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RESUMO 
O crescimento de vasos sanguíneos a partir de vasos pré-existentes – 
Angiogénese – é um processo fundamental durante o desenvolvimento 
embrionário e que contribui também para a homeostasia dos tecidos adultos. 
A vascularização assegura o fornecimento de oxigénio e nutrientes, 
essenciais para o crescimento e reparação dos órgãos. Todos os vasos 
sanguíneos são revestidos por uma monocamada de células endoteliais 
vasculares, considerada um componente essencial no processo angiogénico, 
uma vez que em resposta a diferentes estímulos, as células endoteliais 
migram e proliferam estabelecendo novos vasos sanguíneos. Em condições 
fisiológicas a angiogénese é regulada por um balanço crítico entre factores 
estimuladores (pró-angiogénicos) e inibidores (anti-angiogénicos). No entanto, 
em condições patológicas, como durante o crescimento tumoral, o excesso de 
moléculas estimuladoras induz o crescimento descontrolado de vasos 
sanguíneos facilitando a progressão tumoral e a disseminação de metástases.  
O factor de crescimento do endotélio vascular (VEGF) é um dos reguladores 
mais importantes da resposta angiogénica em células endoteliais vasculares. 
O VEGF é produzido pela maioria das células do organismo em resposta a 
diferentes estímulos como a hipoxia e actua maioritariamente nas células 
endoteliais vasculares promovendo a sobrevivência, proliferação e migração 
destas células. 
Os efeitos biológicos do VEGF são mediados por meio de dois diferentes 
receptores cinase de tirosina, específicos e expressos na superfície destas 
células: o receptor 1 e 2 designados por VEGFR1 (ou FLT1) e VEGFR2 (ou 
KDR). Estudos genéticos demonstraram que tanto o VEGF como os seus 
receptores são necessários para o desenvolvimento normal do sistema 
vascular. Os embriões de murganhos deficitários em qualquer um destes 
genes apresentam letalidade entre os dias E8.5-12.5 do desenvolvimento 
embrionário manifestando graves deficiências na formação inicial dos vasos 
sanguíneos. Diferentes estudos mostraram que apesar da afinidade do VEGF 
ser superior para VEGFR1 relativamente a VEGFR2, é a activação do 
segundo que é responsável pelos efeitos mediados pelo VEGF nas células 
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endoteliais. O modo de acção do VEGF é classicamente descrito através da 
sua ligação ao domínio extracelular do VEGFR2, induzindo a sua dimerizaçao 
e a auto-fosforilaçao de resíduos de tirosina específicos no domínio 
intracelular do receptor. A fosforilaçao destes resíduos gera locais de ligação 
e activação de mensageiros secundários que induzem a activação de 
diferentes vias de transdução de sinal e consequentemente a respostas 
celulares específicas como a proliferação, migração, sobrevivência e 
permeabilidade. Os mecanismos moleculares de acção do VEGF e VEGFR2 
têm sido alvo de numerosos estudos nos últimos 40 anos.  
Recentemente, diferentes publicações mostraram que para além da 
localização na superfície celular, o VEGF e VEGFR2 são também detectados 
no núcleo nomeadamente em tecidos e células leucémicas, in vitro e in vivo. 
Outros trabalhos mostraram a presença de VEGFR2 no núcleo de células 
endoteliais de rato ou bovino. Estas observações abriram, sem dúvida, a 
possibilidade de novos mecanismos de acção exercidos por estas moléculas.  
Assim, no decorrer deste trabalho focámo-nos na investigação dos 
mecanismos moleculares de internalização nuclear do VEGF e VEGFR2 nas 
células endoteliais humanas e na relevância funcional deste processo. 
Na primeira parte deste trabalho, demonstrámos que após um estímulo de 
VEGF, tanto o VEGF como o VEGFR2 são internalizados para o núcleo da 
célula endotelial, num processo dependente de VEGFR1. Verificámos que 
esta mesma internalização é necessária para a reconstituição de uma 
monocamada endotelial após a indução de feridas in vitro. Estes resultados 
revelaram uma nova função biológica já anteriormente descrita dos dois 
receptores de VEGF. Os nossos resultados mostraram também que no 
processo de internalização é necessária a activação da via de sinalização de 
PI3K, e que o mesmo envolve a endocitose mediada por caveolina-1, usando 
os microtúbulos como motores. Para além disto, através da construção de 
mutantes truncados em diferentes resíduos de tirosina na região intracelular 
do VEGFR2, demonstrámos que a fosforilação/activação do VEGFR2 é 
crucial para a translocação nuclear observada. Com o objectivo de identificar 
quais os resíduos de tirosina envolvidos na translocação do receptor, 
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construímos várias proteínas de fusão VEGFR2-GFP usando o VEGFR2 
nativo ou formas mutadas de VEGFR2; nestas um ou dois resíduos de 
tirosina foram convertidos em resíduos de fenilalanina e testámos a sua 
capacidade de serem internalizados para o núcleo de células endoteliais por 
ensaios de microscopia denominados Fluorescence Recovery After 
Photobleaching (FRAP). Os nossos resultados demonstraram que o resíduo 
de tirosina Y951 (localizado em um dos domínios intracelulares do receptor), 
tem uma função importante na translocação nuclear do VEGFR2. 
Na segunda parte deste trabalho focámo-nos na investigação da função do 
receptor VEGFR2 no núcleo das células endoteliais. Num modelo endotelial 
de sobreexpressão de VEGFR2, os nossos resultados mostraram que a 
sobreexpressão nuclear de VEGFR2 estava correlacionada com a expressão 
ou actividade de várias proteínas nucleares. O envolvimento de VEGFR2 na 
actividade transcricional também foi sugerido em ensaios de incorporação de 
5-FU, em que demonstrámos que os níveis de transcrição celulares estavam 
diminuídos e correlacionados com a diminuição dos níveis nucleares de 
VEGFR2. 
Por análise de espectrometria de massa os nossos resultados mostraram que 
em células endoteliais, o VEGFR2 nuclear interage com diferentes proteínas 
nucleares. Confirmámos a interacção de VEGFR2 com o factor de transcrição 
Sp1, envolvido na regulação de diferentes genes importantes para a resposta 
angiogénica. Através de ensaios de imunoprecipitaçao da cromatina (ChIP), 
mostrámos que o VEGFR2 se liga a uma região do seu próprio promotor e à 
qual também se liga Sp1. Estes resultados foram confirmados por ensaios de 
interacção DNA-proteína (EMSA), em que se utilizou a mesma região do 
promotor de VEGFR2. Contudo, os nossos resultados não permitem definir se 
VEGFR2 se liga ao seu promotor interagindo com Sp1. Verificámos ainda que 
a ligação de VEGFR2 ao seu promotor está associada à sua activação 
transcricional. Ensaios repórter usando luciferase, realizados em células 3T3 
que permitiu-nos identificar a região entre -300/-116 (relativamente ao local de 
início da transcrição), como essencial para conferir a actividade transcricional 
dependente de VEGFR2. Para além destes resultados, e por meio de ensaios 
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de ChIP, mostrámos que a ligação de VEGFR2 ao DNA é dependente da 
activação por VEGF, assim como a sua translocação nuclear. Por último e 
reforçando as observações acima descritas, verificámos também que a 
ligação de VEGFR2 ao seu próprio promotor é bloqueada pelo tratamento 
com Bevacizumab ou Sunitinib, dois agentes anti-angiogénicos que inibem a 
activação de VEGFR2.  
O nosso trabalho revela uma nova função do VEGFR2, como um factor de 
transcrição envolvido na regulação da sua própria transcrição e sugere que 
este poderá estar implicado na regulação de outros genes importantes para a 
amplificação da resposta angiogénica. Diferentes estratégias terapêuticas têm 
vindo a ser desenvolvidas com o objectivo de bloquear a activação de 
VEGFR2, enquanto proteína membranar. Contudo, estes inibidores 
angiogénicos não são efectivos em todos os tumores e o benefício é modesto, 
mesmo para os doentes que inicialmente respondem de forma favorável à 
terapêutica, indicando que existem mecanismos de resistência à terapia anti-
VEGF. A análise da actividade transcricional de VEGFR2 nestes tumores e a 
identificação de genes regulados por esta proteína irão certamente contribuir 
para uma maior compreensão da sua função na angiogénese tumoral e na 
descoberta de novos alvos terapêuticos. 
Palavras-chave: Células endoteliais; VEGF; VEGFR2; VEGFR1; 
internalização nuclear; cicatrização de feridas; regulação génica. 
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SUMMARY 
The angiogenic growth of new blood vessels from pre-existing ones is 
fundamental during embryonic development and for normal homeostasis of 
adult tissues. Vascularization ensures the delivery of oxygen and nutrients 
essential for organ growth and repair. Under physiological conditions, a fine 
balance between stimulators and inhibitors regulates the complex process of 
angiogenesis. However, in pathological conditions as tumor progression, the 
stimulus becomes excessive and induces an angiogenic switch that results in 
the uncontrolled growth of blood vessels that facilitates tumor growth and 
metastasis. 
The VEGF/VEGFRs system is a potent regulator of the angiogenic response 
in endothelial cells (ECs). VEGF binds and activates its tyrosine kinase 
receptors VEGFR1 and VEGFR2 at the surface of ECs. In contrast to 
VEGFR1, VEGFR2 has a potent tyrosine kinase activity and is considered the 
major mediator of the signaling responses induced by VEGF. VEGFR2 
phosphorylation at the cell membrane induces the activation of intracellular 
signaling cascades that regulate a wide range of biological responses 
including survival, proliferation, migration and permeability. The molecular 
bases of these processes have been the focus of intensive work for the last 40 
years. Moreover, the discovery of the presence of VEGF and VEGFR2 not 
only at the cell surface but also intracellularly, in particular in the cell nucleus, 
has opened the possibility for new mechanisms of VEGF/VEGFR2 activity. 
In this work we focused on the molecular basis and relevance of the nuclear 
internalization of VEGF and VEGFR2 in ECs. We demonstrated that upon 
VEGF stimulation, both VEGF and VEGFR2 are internalized to the nucleus in 
a VEGFR1-mediated process required for EC recovery following in vitro 
wounding. We also showed that the VEGF/VEGFR2 internalization is 
mediated via caveolae-mediated endocytosis and microtubules and requires 
the activation of the PI3K pathway. By generating several VEGFR2 deletion 
mutants in tyrosine residues we demonstrated that VEGFR2 internalization 
required its phosphorylation. In addition, we showed the importance of the 
tyrosine residue Y951 for the nuclear internalization of VEGFR2.  
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Having established the molecular basis for this nuclear internalization process, 
we focused on the role of VEGFR2 in the nucleus. We showed that VEGFR2 
interacts with the Sp1 transcription factor. We also demonstrated that 
VEGFR2 binds to the Sp1-responsive region of the VEGFR2 proximal 
promoter and that the VEGFR2 binding to DNA is linked to the transcriptional 
activation of the VEGFR2 promoter. This previously unrecognized function of 
nuclear VEGFR2 as a putative transcription factor involved in the regulation of 
its own transcription is a novel mechanism for the amplification of the 
angiogenic response and can be crucial to develop new therapeutic 
approaches associated with angiogenesis-dependent diseases. 
Keywords: Endothelial cells; VEGF; VEGFR2; VEGFR1; nuclear 
internalization; wound healing; gene regulation. 
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SCOPE OF THE THESIS  
This thesis is organized in five chapters. Chapter I is a general introduction 
where I describe the different mechanisms underlying the formation of blood 
vessels in physiological and pathological conditions and the function and 
regulation of the VEGF/VEGFR system in these processes. 
In Chapters II, III and IV I present the results obtained on the molecular 
mechanisms and relevance for the nuclear internalization of VEGF/VEGFR in 
ECs. Each Chapter is organized as: Abstract, Introduction, Results, 
Discussion, Material and Methods, Acknowledgements, References. In 
Chapters II and IV additional Supplementary Results and Supplementary 
References were included. 
In Chapter II, I present our results published in the paper: Constantino Rosa 
Santos S, Miguel C, Domingues I, Calado A, Zhu Z, Wu Y, and Dias S. VEGF 
and VEGFR2 (KDR) Nuclear Internalization Is Required For Endothelial 
Recovery During Wound Healing. Exp Cell Res, 2007. 313(8): p. 1561-74. 
We described that VEGFR2 translocates to the nucleus of ECs upon VEGF 
stimulation, in a process mediated by VEGFR1.The translocation process 
requires the activation of the PI3-kinase pathway and is linked to a caveolae-
mediated endocytic pathway, via microtubules. We also focused on the role of 
VEGFR2 phosphorylation in the process of nuclear internalization. By 
generating different VEGFR2 tyrosine deletion mutants, we showed that the 
VEGF-induced VEGFR2 internalization was impaired, suggesting that the 
activation of the receptor is involved in its nuclear translocation.  
In Chapter III, I describe our results concerning the role of the VEGFR2 
tyrosine residues in the nuclear translocation process. We generated tyrosine 
to phenylalanine point mutants and established its expression in an EC model. 
We analyzed the internalization dynamics of these mutants compared to 
VEGFR2 wild-type (WT) by FRAP and identified the tyrosine residue Y951 in 
the kinase insert domain as essential for the nuclear translocation of VEGFR2. 
Some of these results were included in the revised manuscript version shown 
in Chapter IV. 
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In Chapter IV, I present our results obtained on the function of nuclear 
VEGFR2, submitted to PloS One in the paper: Domingues I, Rino, J, 
Demmers JAA, de Lanerolle P and Constantino Rosa Santos S. VEGFR2 
Translocates to the Nucleus to Regulate its own Transcription. We showed 
that nuclear VEGFR2 interacts with several nuclear proteins, identified by 
mass spectrometry analysis, including the Sp1 transcription factor. By in vivo 
chromatin immunoprecipitation (ChIP) assays, we found that VEGFR2 binds to 
the Sp1-responsive region of the VEGFR2 proximal promoter. By reporter 
assays, we showed that the VEGFR2 DNA binding is directly linked to the 
transcriptional activation of the VEGFR2 promoter. Overall, we demonstrate a 
new mechanism by which VEGFR2 activates its own promoter that could be 
involved in amplifying the angiogenic response.  
Chapter V is a final discussion of the key findings obtained throughout this 
thesis and the putative relevance of the new mechanisms described for the 
angiogenesis field. 
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1. THE FORMATION OF BLOOD VESSELS 
Oxygen and nutrients are essential for cell growth and homeostasis. In 
primitive and smaller organisms, oxygen simply diffuses to all the cells in the 
body. Throughout evolution larger and complex organisms developed a 
network of blood vessels containing carrier molecules to deliver oxygen and 
nutrients to distant organs and remove the metabolic waste, contributing to 
body homeostasis [1]. In vertebrates, the cardiovascular system is a closed 
blood circuit pumped from the heart through arteries that ramify in smaller 
arterioles and into capillary beds [2]. The blood then returns through venules 
and veins to the heart [2]. 
The capillaries are composed of endothelial cells (ECs) surrounded by a 
basement membrane and a sparse layer of pericytes [3]. The capillary bed is 
the largest surface of the vascular system and due to its wall structure these 
vessels form the main site for exchange of gases and nutrients with the 
surrounding tissues [2,3]. The capillary endothelial layer presents distinctive 
characteristics depending on the different organs or tissues conferring different 
levels of permeability. The endothelial layer is continuous in the muscle tissue 
and discontinuous in the liver sinusoids, while in the kidney is fenestrated. The 
blood-brain barrier has further specialized ECs that are impermeable to 
various molecules [3]. Arterioles and venules have an increased coverage of 
pericytes and smooth muscle cells (SMC) compared to capillaries. The 
vascular SMCs from the precapillary arterioles are tightly packed with the 
endothelial layer and form their own basement membrane.  
The walls of larger vessels are composed of additional specialized layers that 
ensure the transport of blood to and from the heart [2]. The inner layer of 
arteries and veins, tunica intima is composed of ECs surrounded by a 
basement membrane. A middle layer named tunica media is composed of 
SMCs and elastic fibers that control the vessel diameter and the blood flow. 
The outer layer, tunica adventitia is composed of connective tissue, collagen 
fibers and nerves and has its own blood supply named vasa vasorum [3]. 
GENERAL INTRODUCTION 
 
 4 
Although the walls of arteries and veins are composed of these same layers, 
both present different caracteristics as a result of the pressure and direction of 
the blood flow. The medial layer in arteries is a robust muscular sheet that 
ensures the high arterial blood pressure. In contrast blood flows with a lower 
pressure in veins and as a result, their wall is thinner than arteries with 
additional semi-lunar valves, which prevent the blood from flowing backwards 
[2,3].  
The molecular mechanisms underlying the formation of blood vessels will be 
further discussed.  
1.1. VASCULOGENESIS AND ANGIOGENESIS 
The first step in the formation of blood vessels is the differentiation of vascular 
ECs, which line the inner surface of all blood vessels. In an early phase of the 
vasculogenesis, a subset of mesodermal precursors, the hemangioblast, is 
committed to differentiate into angioblasts and primitive haematopoietic cells 
[4], (Figure 1).  
 
 
Figure 1. Vasculogenesis. 
The mesodermal precursors differentiate in hemangioblasts, the bipotential precursors of angioblasts 
and hematopoietic cells. The angioblasts aggregate at the surface and the hematopietic precursors in 
the center of the blood islands in the yolk sac. The angioblasts then differentiate into ECs and form the 
primary vascular plexus with the first blood cells in circulation. Adapted from [4]. 
The angioblasts aggregate in the periphery and the hematopoietic precursors 
accumulate in the middle of the blood islands in the yolk sac and embryo [4]. 
The angioblasts then differentiate into ECs to form simple tube-like structures 
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and organize the primary vascular plexus [4]. The progressive expansion and 
remodelling of the primary network of vessels occurs by ramification of larger 
vessels into smaller ones (intussusceptive growth) or by sprouting and 
proliferation from the existing vessels, a process named angiogenesis [5], 
(Figure 2). 
 
Figure 2. Angiogenesis. 
Blood vessels arise from pre-existing capillaries. A VEGF gradient induces the angiogenic program. 
First, pericytes (in green) detach and blood vessels dilate. The extracellular matrix (ECM, in grey) is 
degraded. ECs (pink) polarize and start to migrate. The leading “tip” cells extend filopodia towards the 
angiogenic stimuli while adjacent “stalk” cells proliferate, loosely following each other. Behind the 
migration columns, ECs adhere to each other and create a lumen, which is accompanied by ECM 
deposition and pericyte attachment. Finally, blood-vessel sprouts fuse with other sprouts to build new 
circulatory routes. Adapted from [6,7]. 
In these early stages of vasculogenesis and angiogenesis the first identified 
member of the Vascular Endothelial Growth Factor (VEGF) family of 
glycoproteins, VEGFA, and its receptors VEGFR1 and VEGFR2 are key 
players. Genetic studies have shown their requirement for the normal 
development of the vascular system [8]. Embryos deficient for any of these 
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molecules die in utero around embryonic day (E)8.5-12 exhibiting profound 
defects in early vessel formation [9,10,11,12], (see below). VEGFA is 
produced by the majority of the cells, in response to different stimuli, such as 
hypoxia (see below) and acts in a paracrine fashion on ECs, which express 
the receptors VEGFR1 and VEGFR2 [8]. 
The angiogenic program is activated when in response to VEGF, specialized 
endothelial ‘tip’ cells loose the cell – cell contacts, detach from the vascular 
wall and selectively degrade the ECM [7], (Figure 2). At the front of a sprout, 
highly polarized and motile endothelial “tip” cells extend filopodia to guide a 
sprouting vessel towards the angiogenic stimulus [13]. Following behind the tip 
cells, endothelial “stalk” cells proliferate to elongate the vessel branch [7], 
(Figure 2). Each of these EC phenotypes (tip and stalk ECs) has a distinct 
molecular signature. However, these phenotypes are not permanent, but, are 
plastically regulated by the axis Notch, its ligand Delta-like-4 (DLL4) and 
VEGF-VEGFR signaling [13]. The DLL4/Notch model predicts that ECs, 
exposed to the highest VEGFA levels, gain a competitive advantage to acquire 
a tip-cell fate and position in the sprout [13]. Recent findings suggested that 
ECs dynamically compete with each other for the tip cell position [14]. VEGFA 
induces an upregulation of DLL4 and consequently, this tip cell produces more 
DLL4 than its neighboring cell [13,15,16,17,18,19]. The elevated levels of 
DLL4 activate Notch signaling in neighboring cells and consequently, VEGF-
signaling is reduced, inducing a decreased DLL4 expression 
[13,15,16,17,18,19]. As a result, the tip cell suppresses the same response in 
stalk cells, which progressively lose competition for the tip [13,15,16,17,18,19]. 
It was shown that VEGFR levels act upstream of Notch in the selection 
process by regulating DLL4 levels [14]. Cells with reduced VEGFR2 levels 
hardly adopt the tip cell position [14]. Tip cell competition through VEGFR 
levels establishes a biological function for the dynamic VEGFR regulation 
during sprouting angiogenesis [14]. A critical step in the angiogenic process is 
the recruitment of pericytes to the newly formed vessels as these cells are 
essential for the maturation of endothelial tubes into blood vessels [20]. 
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1.2. MATURATION OF BLOOD VESSELS 
The coverage of vessels with pericytes and smooth muscle cells (SMC) 
contribute to the regulation of vessel perfusion and the maintenance of a 
mature vasculature, a process named arteriogenesis [1,21]. Pericytes are 
embedded within the basement membrane of the endothelium and 
communicate with ECs through gap junctions or paracrine signaling pathways. 
Pericytes have gained attention in recent years as potential new targets for the 
anti-angiogenic therapies discussed below [22]. 
The platelet-derived growth factor " (PDGF")/ PDGF receptor " (PDGFR") 
and angiopoietin/Tie2 signaling systems are important regulators of the blood 
vessel maturation [3]. PDGF" secreted by ECs in response to VEGF recruits 
pericytes and SMC to the growing vessels by signaling through PDGFR" [23]. 
In agreement with this, Pdgf!!/! and Pdgfr!!/! knockout mice are embryonic 
lethal presenting severe hemorrhage and edema due to the immature vessels 
that fail to attract pericytes [23].  
Also important for vessel growth and maturation is the endothelial specific- 
TIE2 tyrosine kinase receptor and two ligands of the angiopoietin (ANGPT) 
family, ANGPT1 and ANGPT2 expressed in SMC and ECs respectively. 
ANGPT1 is required for the correct organization and maturation of the newly 
formed vessels presumably by facilitating the EC-SMC interconnection 
through the activation of TIE2 [3]. Consistent with this, Angpt1!/! and Tie2!/! 
deficient mice are also embryonic lethal, having similar phenotypes 
characterized by severe defects in vascular remodelling and maturation 
[24,25]. ANGPT2 plays a double role depending on the presence or absence 
of VEGF [26]. In the absence of VEGF, ANGPT2 acts as an antagonist of 
ANGPT1 leading to the regression of blood vessels. In the presence of VEGF, 
ANGPT2 facilitates vascular remodelling, inducing vessel destabilization 
[26,27]. Additionally, other signaling molecules, such as the transforming 
growth factor " (TGF") and the sphingosine-1-phosphate receptor (S1PR1), 
are also involved in the vessel maturation processes [3,21]. 
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The concerted action of these molecules results in the establishment of a large 
and highly organized vascular network, with larger vessels that progressively 
ramify into smaller vessels, terminating in capillaries and contributing to organ 
growth [1]. 
1.3. ENDOTHELIAL CELL SPECIFICATION 
Although the molecular processes underlying the arterial-venous EC 
specification are not fully understood, increasing evidence suggest that this 
process is regulated by the concerted action of different molecules [28]. Two 
members of the Eph-Ephrin subclass of receptor tyrosine kinases, the ligand 
ephrinB2 and its receptor EphB4, are specific markers for arteries or veins 
respectively [29]. These markers are detected in blood vessels of the embryo 
before a proper circulation is observed, indicating that the arterial-venous 
commitment occurs early in development [29]. Consistent with this, genetic 
studies demonstrated that EphrinB2!/! [29] and EphB4!/! [30] knockout mice 
exhibited defects in remodeling of the primary capillary plexus into arteries and 
veins. However, the action of other upstream factors seems to be required for 
the determination of arterial or venous EC fate [31].  
Among these factors, the Notch pathway has been shown to have a crucial 
role in arterial–venous specification in vivo, promoting arterial EC commitment 
and repressing venous differentiation [28]. The receptor Notch4 and the ligand 
DLL4 are both specifically expressed in arteries [32,33]. Consistently, 
Notch1/4!/! and Dll4!/! mice display defects in vascular development, including 
arterial specification [34,35]. In Dll4!/! mice disrupted arterial EC differentiation 
is accompanied by decreased EphrinB2 expression and simultaneously 
increased EphB4 expression [34]. Studies in zebrafish have shown that Sonic 
Hedgehog and VEGF act upstream of Notch in the regulation of the arterial 
fate [36].  
Conversely, the orphan receptor COUP-TFII is specifically expressed in 
venous, but not in arterial ECs [37]. The conditional inactivation of COUP-TFII 
in ECs results in the acquisition of arterial characteristics in veins and 
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increased expression of arterial markers such as Notch4 and EphrinB2 [37]. 
These results suggested that COUP-TFII promotes the venous cell fate by 
suppressing the Notch pathway [28].  
Another important form of endothelial differentiation is the formation of the 
lymphatic ECs. Around E10 of mouse development a subpopulation of venous 
ECs expressing the prospero homeobox transcription factor Prox1 trans-
differentiates into lymphatic ECs [38]. The molecular mechanisms for growth, 
migration and survival of the lymphatic ECs are also intimately related to 
members of the VEGF family of ligands and receptors, most particularly 
VEGFC and FIGF (previously named VEGFD) and the VEGF receptor 3 
(VEGFR3), [39,40]. 
2. PHYSIOLOGICAL AND PATHOLOGICAL ANGIOGENESIS 
In adulthood, the vasculature remains quiescent and angiogenic processes 
occur only in specific situations, such as wound healing, the regeneration of 
the endometrium during the menstrual cycle or in the placenta during 
pregnancy [1]. Quiescent ECs retain the ability to rapidly migrate and 
proliferate in response to different stimuli [1]. Therefore, in physiological 
situations, the angiogenic events that occurred during normal vascular 
development in the embryo are reactivated [8]. Conversely, a de-regulation of 
the angiogenic process contributes to many malignant, inflammatory, 
ischemic, infectious and immune disorders [41]. Several diseases are 
characterized by excessive angiogenesis, such as cancer, age-related 
macular degeneration (AMD) and rheumatoid arthritis among others [21]. 
However, insufficient angiogenesis also characterizes several diseases. Heart 
ischemia, hypertension, atherosclerosis and diabetes are some examples of 
processes where insufficient angiogenesis can be observed [21]. The great 
impact that angiogenesis has in health and disease has been pushing the 
research towards the study of the molecular mechanisms that regulate this 
process. 
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2.1. ANGIOGENIC BALANCE 
Angiogenesis is a complex process regulated by a fine-tuned balance of pro- 
and anti-angiogenic molecules. In adults, the balance can be disrupted to 
favor increased blood vessel formation in physiologic repair settings (such as 
wound healing) but also in many pathological conditions (such as cancer). A 
classical view of this model proposes that in a quiescent state, the balance 
between angiogenic stimulators and inhibitors favors inhibition and 
consequently capillary growth is restrained [42]. Additionally, it was recently 
proposed that a dynamic equilibrium exists between of pro- and anti-
angiogenic factors. The physiologic status of this balance could determine the 
predisposition of an individual to turn the switch “ON” during pathologic events 
[43]. 
Several positive regulators of angiogenesis have been described, including 
growth factors and cytokines, such as VEGF, placental growth factor (PlGF), 
fibroblast growth factors (FGFs), PDGF", transforming growth factor # and " 
(TGF#/"), tumor necrosis factor-alpha (TNF#) and interleukin 3 and 8 (IL3, 
IL8) among others [44]. The action of negative angiogenic regulators, such as 
thrombospondin 1 (THBS1), angiostatin (fragment of plasminogen) and 
endostatin (fragment of type VIII collagen that binds integrins), balances the 
effect of the pro-angiogenic molecules [44]. In a physiological situation like 
wound healing the release of pro-angiogenic molecules into the wound bed 
after injury shifts the local equilibrium between stimulators and inhibitors 
towards vascular growth, driving the quiescent ECs to begin the angiogenic 
program. The newly formed vessels rapidly mature and become stable [6]. 
However, under certain pathological conditions, such as tumors, local 
inhibitory controls are unable to contain the augmented activity of angiogenic 
inducers promoting the “angiogenic switch” [6]. In these conditions a disruption 
in the angiogenic balance is under the control of both the genetic composition 
of any individual cancer cell and its microenvironment within the tumor. [6]. 
Tumors described as “wounds that never heal” have a constant growth of new 
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blood vessels that fail to became quiescent [6,45]. VEGF signaling mediated 
by VEGF receptors is considered one of the most important factors for the 
activation of the angiogenic events both in physiological and pathological 
settings [1]. The VEGF-mediated effects in wound healing and tumor 
angiogenesis will be further analyzed. 
2.2. WOUND HEALING 
The healing process after injury follows a series of overlapping phases 
including angiogenesis, inflammation, re-epithelialization and tissue 
remodeling [46]. After injury, a fibrin/fibronectin-rich clot is formed at the 
wound site and the granulation tissue fills the wound bed [46]. A good 
vascularization ensures the delivery of oxygen, nutrients, and immune/stem 
cells to facilitate repair [46]. The release of several growth factors and 
cytokines such as VEGF induces the migration and proliferation of ECs to the 
wound bed [46,47]. The inflammatory response is initiated with the recruitment 
of circulating monocytes and macrophages through the activation of VEGFR1 
by VEGF [46]. The endothelial plexus is further stabilized by the recruitment of 
pericytes and establishment of cell-cell and cell-ECM interactions through the 
activation of integrins and cadherins, contributing to the physiological tissue 
repair [46]. Failure or insufficient blood vessel formation impedes adequate 
cellular responses to heal and thus the tissue repair is delayed or blocked, 
leading to chronic ischemic wounds [48]. 
2.3. TUMOR ANGIOGENESIS 
Early tumor formation is based on a succession of genetic and epigenetic 
alterations leading to an increased proliferation rate and/or decreased cell 
apoptosis that progressively guide the conversion of normal cells into cancer 
cells [49]. Like normal tissues, tumors require the constant supply of oxygen 
and nutrients allowing them to grow beyond a certain size. In 1971, Dr. Judah 
Folkman proposed that tumor growth and metastasis are angiogenesis-
dependent and therefore the inhibition of angiogenesis (anti-angiogenesis) 
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would be a successful strategy to manage tumor growth [50]. Folkman, often 
considered as “the father of the tumor angiogenesis field”, also hypothesized 
that a factor produced by tumor cells (tumor angiogenesis factor – TAF) and 
mitogenic to ECs would stimulate the formation of new vessels. VEGF was 
later identified [51,52] as being the angiogenic factor proposed and partially 
isolated by Folkman [53]. Since then, researchers worldwide have identified 
several of the pro- and anti-angiogenic molecules described above.  
Solid tumors are highly complex structures composed of neoplastic cells and 
stroma. Tumor cells actively recruit stromal cells such as tumor-associated 
fibroblasts, ECs, pericytes and SMCs that contribute for the tumor 
microenvironment and play an important role in the initiation and progression 
of tumors [54]. 
Classically, tumor-growth is composed of two phases: an initial avascular 
phase that corresponds to a small mass of neoplastic cells that grows until    
1-2 mm [6]. These so-called in situ or dormant tumors need to recruit their own 
blood supply to ensure the delivery of oxygen and nutrients allowing tumor 
growth [6,55]. Interestingly, these dormant lesions were found during 
autopsies of individuals who died of causes other than cancer, suggesting that 
only a subset of these tumors enter the second vascular phase [6,55]. 
Angiogenesis is therefore considered a rate-limiting step in tumor growth and if 
the “angiogenic switch” is not turned “ON”, tumors can stay dormant by 
reaching a balance between cell proliferation and cell death [6,54,55]. Both 
tumor and stromal cells that enter the vascular phase secrete an excess of 
pro-angiogenic factors stimulating a switch in the angiogenic phenotype and 
leading to the activation of the “angiogenic switch” [54]. This results in the 
expansion of the tumor mass that becomes more likely to metastasize and is 
potentially lethal [54]. 
VEGFA is expressed in most tumors and its expression correlates with tumor 
vessel density and growth [6]. VEGFA-stimulated ECs mitogenesis and 
permeability are primarily mediated by VEGFR2 [56]. Tumor vessels are 
architecturally different from normal blood vessels, exhibiting an irregular, 
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dilated and tortuous shape. Consequently, they are characterized by a 
variable diameter and irregular blood flow. The increased and constant 
production of VEGFA is partly responsible for the leaky and tortuous 
phenotype of the tumor vessel network [7]. These vessels also do not mature 
properly and show a poor coverage with pericytes and SMCs, which 
contributes for a decreased blood flow. As a consequence nutrients and 
oxygen are not correctly delivered and the tumor remains hypoxic, resulting in 
the constant overproduction of VEGFA and abrogation of a normal vessel 
phenotype [54]. Other members of the VEGF family, such as PlGF, are 
responsible for an enhanced activation of the VEGFA-VEGFR2 mediated 
responses, contributing to constant vessel growth [57] (see below). The 
observation that tumor cells (solid and hematologic tumors) express not only 
VEGF but also its receptors, suggested that autocrine loops might also 
mediate tumor growth [58,59]. Interestingly, it has been reported that VEGF 
and its receptors may localize not only to the cell surface but also internally 
[60,61], promoting cell survival via intacrine loops [60]. 
The importance of the VEGF/VEGFR contribution for tumor angiogenesis led 
to the development of anti-angiogenic therapies targeting this system [62]. 
Different monoclonal antibodies as well as several small molecule inhibitors of 
the VEGFRs have also been developed [63], (Table 1). 
In February 2004, Bevacizumab (Avastin®, Genentech, Roche) became the 
first anti-angiogenic drug to receive approval from the Food and Drug 
Administration (FDA, USA) for treatment of metastatic colorectal cancer in 
combination with 5-fluorouracil-based chemotherapy [64]. Bevacizumab is a 
humanized monoclonal antibody that binds to and inhibits the biological 
activity of all VEGFA isoforms [64]. The small molecule inhibitors target the 
ATP-binding site of the receptors blocking the downstream intracellular 
signaling pathways [62,63]. 
Sunitinib (Sutent®, Pfizer) is a multi-targeted receptor tyrosine kinase (RTK) 
inhibitor of VEGFRs, PDGFRs and RET, which exhibits anti-tumor activity [65] 
GENERAL INTRODUCTION 
 
 14 
and has been approved by the FDA for the treatment of advanced renal cell 
carcinoma [66]. 
These and other agents have prolonged the life of numerous cancer patients 
and have revolutionized the face of clinical oncology. However, clinical 
experience also showed that VEGF-targeted therapy often prolongs overall 
survival of patients by only months, without offering an enduring cure [67]. 
Recent studies in mice have shown that although these VEGF-targeted drugs 
inhibit primary tumor growth, they may also promote tumor invasiveness and 
metastasis, decreasing the survival rates [68,69].  
Table 1. FDA-approved anti-angiogenic therapies. Monoclonal antibodies and small molecule 
tyrosine kinase inhibitors targeting angiogenesis. 
 
These findings contribute to understand the intrinsic and evasive resistance to 
these drugs [67]. Therefore, it is crucial to develop new strategies that will 
allow us to optimally exploit the potential of VEGF therapy to block primary 
tumor growth, while at the same time suppressing pro-metastatic effects. 
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3. VEGFS AND VEGF RECEPTORS – THE REGULATORS OF ANGIOGENESIS 
VEGFs are secreted, dimeric glycoproteins that belong to the cysteine-knot 
growth factor superfamily [70]. VEGFs contain an approximately 100 amino 
acid VEGF homology domain characterized by eight spaced cysteine 
residues, structurally related with PDGF [70]. The VEGF family consists of 
seven members [71]: five of them, namely VEGFA (the original form of VEGF), 
PlGF, VEGFB, VEGFC and c-fos induced growth factor (FlGF, previously 
named vascular endothelial growth factor D) are present in mammals. The 
other two members are the parapoxvirus VEGFE and the snake venom VEGF 
(svVEGF) [72]. Although VEGFs usually form homodimers, the formation of 
heterodimers between VEGFA and PlGF [57,73] or VEGFA and VEGFB [74] 
has been reported. The different members of the VEGF family interact with a 
set of cell-surface receptors that initiate signal transduction cascades in 
response to these factors [71], (Figure 3).  
These three closely related receptors are members of the RTK superfamily: 
VEGFR1, VEGFR2 and VEGFR3 (described in detail further below), [71,75]. 
Additionally, VEGF interacts with a class of co-receptors, neuropilin 1 (NRP1) 
and NRP2, initially described as semaphorin receptors involved in axon 
guidance in the nervous system, that have been shown to modulate VEGF 
binding to the main receptors [71,75]. 
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Figure 3. The VEGF ligand family and their receptors. 
The VEGF family includes VEGFA, B, C, E, FIGF, snake venom (sv) and placenta growth factor 
(PlGF), which have different binding properties to three different receptor tyrosine kinases, VEGFR1 
(green), VEGFR2 (blue) and VEGFR3 (purple). Additionally, VEGFs and VEGFRs bind to co-receptors 
such as neuropilins. The extracellular domain of VEGFR1 is also expressed as a soluble protein 
(sVEGFR1). Both PLGF and VEGFB are selective ligands for VEGFR1. VEGFE is a selective ligand for 
VEGFR2. Snake venom VEGF (svVEGF) isoforms bind to VEGFR1 and/or VEGFR2. Unprocessed 
VEGFC and FIGF are selective ligands for VEGFR3. VEGFA isoforms bind sVEGFR1 and VEGFR2. 
Proteolytic processing of VEGFC and FIGF allows for binding to VEGFR2. Adapted from [71,72,75]. 
3.1. VEGFA 
VEGFA was the first identified member of the VEGF family. It was first partially 
purified in Harold Dvorak’s laboratory in 1983 from the conditioned media of a 
guinea-pig tumor cell line and initially described as vascular permeability factor 
(VPF) since it was able to induce vascular leakage in the skin [52]. In 1989, 
Ferrara and Henzel described the EC specific-mitogenic activity of a molecule 
designated VEGF [51] and the molecular cloning of VEGF [76] and VPF [77] 
later that year demonstrated that these were the same molecule. These 
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findings showed that VEGF was an endothelial-specific mitogen and 
permeability inducer suggesting that it could be a critical regulator of the 
physiological and pathological growth of blood vessels [78]. 
Genetic studies further demonstrated the importance of VEGFA for normal 
vascular development since the loss of a single VEGFA allele in mice resulted 
in embryonic lethality between E11-12 [9,10]. Both Vegfa!/! null and Vegfa+/! 
heterozygous embryos show abnormal vascular development with several 
defects in the cranial region and heart [10], presenting decreased EC density 
and proliferation, with smaller calibre vessels and a disorganized vascular 
plexus [9]. The severe phenotypes observed indicated that decreased VEGFA 
levels below a certain threshold during embryonic development results in 
disruption of normal organogenesis [10]. The critical VEGFA gene-dosage 
dependence during development was also observed in mice overexpressing 
VEGFA. In particular, disruption of the regulatory 3! untranslated region (UTR) 
of the Vegfa gene led to a 2-3 fold expression increment resulting in 
embryonic death at E12.5 due to cardiac failure [79]. 
An additional level of complexity in the regulation of VEGFA results from 
alternative splicing of the eight exons that compose the VEGFA gene [63]. 
Several isoforms are generated containing 121 to 206 amino acids after signal 
sequence cleavage in humans and one amino acid less in mice: VEGFA121, 
VEGFA145, VEGFA162, VEGFA165, VEGFA165b, VEGFA183, VEGFA189 and 
VEGFA206 [80,81], (Figure 4).  
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Figure 4. The splicing variants of the human VEGFA gene. 
The gene encoding VEGFA consists of eight exons encoding different structural motifs. Alternative 
splicing of a single pre-mRNA species produces at least eight different VEGFA isoforms that vary in 
total amino acid number: VEGFA121, VEGFA145, VEGFA162, VEGFA165, VEGFA165b, VEGFA189 and 
VEGFA206. VEGFA165 is the predominant isoform. Isoforms VEGFA145, VEGFA162 and VEGFA183 are 
less frequent. Adapted from [70,72,75]. 
VEGFA121, VEGFA165 and VEGFA189 are preferentially expressed isoforms, 
presenting a wide tissue distribution [70]. These isoforms display different 
abilities to bind heparin, heparan sulphate proteoglycans (HSPGs) and ECM, 
due to the presence or absence of the sequences encoded by exons 6 and 7 
[80,81], (Figure 4).  
The increased affinity to heparin regulates the functional activity of VEGFA189 
and VEGFA206 isoforms, as they are kept sequestered in the ECM and cell 
surface, only becoming available once released by heparinases or from 
proteolysis following plasminogen activation [81,82,83]. By contrast, VEGFA121 
that lacks exons 6 and 7 does not bind heparin and is a freely diffusible 
protein. VEGFA165, the predominant VEGFA isoform, contains only the 
heparin-binding domain encoded by exon 7 and is therefore moderately 
diffusible and is the major inducer of the VEGF activity [70,82]. VEGFA165b is 
another VEGFA165 isoform, which results from the use of an alternative distal 
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splice acceptor site in exon 8 and has been proposed to be a natural 
antagonist of VEGFA165 [84,85].  
We are still far from understanding the relative contributions of the different 
isoforms to the VEGFA physiological activities. Genetic studies have shown 
the requirement of the heparin-binding VEGFA isoforms. In particular mice 
expressing exclusively the VEGFA120 isoform (Vegfa120/120) die shortly after 
birth due to cardiac failure and present deficiencies in vascular outgrowth, 
impaired myocardial angiogenesis [86] and retarded bone development [87]. 
Therefore, the absence of VEGFA164 and VEGFA188 in mice leads to ischemic 
cardiomyopathy [86], demonstrating the functional importance of the two 
heparin-binding domain encoded in exons 6 and 7 of the VEGFA-expressing 
isoforms. Mice expressing exclusively the VEGFA188 isoform (Vegfa188/188) 
displayed impaired retinal arterial development although normal venular 
growth was reported [88]. Vegfa188/188 mice also showed impaired 
vascularization surrounding the epiphysis, resulting in the defective 
development of secondary ossification centers among other bone deficiencies 
[87]. This indicates that this isoform alone is able to fulfil many, but not all the 
functions of VEGFA. Interestingly, mice expressing exclusively the VEGFA164 
isoform (Vegfa164/164) are viable and healthy indicating that this isoform is 
sufficient for the normal outgrowth and remodeling of blood vessels [89]. 
VEGFA gene expression is controlled at different levels including transcription, 
mRNA stability, alternative splicing and translation [90]. Hypoxia is one of the 
best studied stimulus regulating VEGFA gene expression and is considered 
essential for the development of new blood vessels during embryonic 
development and for tumor vascularization [90]. VEGFA gradients attract and 
guide the sprouting ECs to the most oxygen-depleted areas in the tissue 
reflecting the nutrient needs of the cells. Hypoxia-inducible factor 1 (HIF1) is 
an oxygen-regulated transcriptional activator that functions as a master 
regulator of oxygen homeostasis [91]. HIF1 is a heterodimer composed of 
HIF1# and HIF1" subunits. Whereas HIF1" is constitutively expressed, HIF1# 
expression is induced in hypoxic cells with an exponential increase in 
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expression as cells are exposed to low O2 concentrations [91]. In non-hypoxic 
conditions, HIF1# is ubiquitinated and subjected to proteasomal degradation 
[91] Under hypoxic conditions, the fraction of HIF1# that is ubiquitinated 
decreases dramatically, resulting in an accumulation of the protein [91]. A 
functional hypoxia response element (HRE) in the 5’ region of the VEGFA 
human promoter was found to bind the heterodimer HIF1"/HIF1# [92].  
In addition to this major regulator, other transcription factors such as Sp1 and 
AP-2 were found to regulate the VEGFA gene expression by hypoxia-
independent mechanisms, triggered by distinct stimuli [90].  
3.2. VEGF-RELATED PROTEINS 
3.2.1. PLGF 
PlGF was first isolated from a placenta cDNA library and identified as a 
VEGFA homolog [93]. PlGF is also expressed in the heart, lung, thyroid and 
skeletal muscle, although at low levels [94]. PlGF is a $ 46 kDa dimeric 
secreted glycoprotein that shares 42% amino acid sequence homology with 
VEGFA [95]. The human gene for PlGF is encoded by 7 exons that undergo 
alternative splicing generating 3 isoforms: PlGF-1, PlGF-2 and PlGF-3 [96,97]. 
Another PlGF isoform termed PlGF-4 was isolated from human trophoblasts 
[98]. The predominant isoforms PlGF-1 (134 amino acids) and PlGF-2 (152 
amino acids) differ in size by the insertion of a basic 21-amino acid stretch 
encoded by exon 6 that enables PlGF-2 to bind heparin [97] and NRP1 [99]. 
The biological effects of PlGF are still under debate due to the apparent 
contradictory results obtained so far. For instance, PlGF alone has 
demonstrated little mitogenic and permeability-enhancing activity in vitro or in 
vivo, but it was able to potentiate the effects of low concentrations of VEGF 
[100]. Consistent with this, the Plgf!/! knockout mice presented normal 
vascular development [101]. However, PlGF deficiency impaired angiogenesis 
and permeability during ischemia and wound healing and also in pathological 
conditions as inflammation and cancer [101]. Different hypotheses have been 
raised to explain the differential role of PlGF in developmental and 
CHAPTER I 
 
21 
pathological angiogenesis. Since PlGF is a selective and high affinity ligand for 
VEGFR1 it was suggested that it could displace VEGF bound to VEGFR1 and 
therefore increased its availability to bind VEGFR2 [100]. Another important 
feature of PlGF is its ability to naturally form heterodimers with VEGFA [73], 
which are potentiated under pathological conditions such as cancer [102]. The 
VEGFA/PlGF heterodimers, but not PlGF homodimers were able to induce 
mitogenic effects as potent as VEGFA homodimers in vitro [73]. Furthermore, 
VEGFA/PlGF heterodimers are able to bind not only VEGFR1, but also 
VEGFR2 and enhance angiogenesis by activation of intermolecular VEGF 
receptor crosstalk through the formation of VEGFR1/VEGFR2 heterodimers 
(further discussed below), [57]. 
3.2.2. VEGFB 
VEGFB was the third VEGF ligand identified as selectively binding VEGFR1 
[74,103]. VEGFB shares 45% homology with VEGFA [104]. The human gene 
for VEGFB is organized in 7 exons [105] and alternative splicing of the exon 6 
generates two isoforms: VEGFB167 [106] and VEGFB186 [104]. VEGFB167 
contains a highly basic C-terminus domain encoded by exon 6b highly 
homologous to sequence encoded by exon 7 in VEGFA165 [104]. Like 
VEGFA165, VEGFB167 binds heparin and the ECM, while VEGFB186 is freely 
secreted from cells [104]. VEGFB167 is the predominant isoform in vivo being 
highly expressed in the heart, skeletal muscle and pancreas [104]. VEGFB is 
also able to heterodimerize with VEGFA165 in vitro [104,106]. However, the 
biological significance of the heterodimers in vivo remains to be determined. 
Additionally, Vegfb!/! knockout mice are healthy and fertile, although these 
animals showed a reduced heart size and displayed a deficient recovery from 
experimentally induced ischemia [107]. Although the precise function of 
VEGFB is still unclear, these findings suggest a role in the establishment of a 
functional coronary vasculature [107]. 
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3.2.3. VEGFC AND FIGF 
VEGFC and its homologue FIGF (c-fos induced growth factor previously 
named vascular endothelial growth factor D) constitute a subfamily of VEGF 
ligands characterized by unique N- and C-terminal extensions of the VEGF-
homology domain [74,108,109]. VEGFC and FIGF are secreted as 
homodimeric precursor proteins that undergo proteolytic processing. The      
C-terminal domain is cleaved upon secretion, remaining bound to the            
N-terminal portion of the protein by disulphide bridges. Upon further proteolytic 
processing of the N-terminal, the mature protein is released and comprises 
only the VEGF-homology domain [40,110]. The proteolytic processing of both 
VEGFC and FIGF modulates receptor-binding affinities, since the mature 
forms are able to bind both VEGFR2 and VEGFR3, while the unprocessed 
forms bind exclusively VEGFR3 [40,110]. Vegfc!/! knockout mice die in utero 
at E15.5 due to large tissue edema as a result of the deficient lymphatic 
system [111]. Vegfc!/! lymphatic endothelial cells fail to sprout from embryonic 
veins to form the lymph vessels. However, the commitment to the lymphatic 
lineage is not abrogated, indicating that VEGFC is crucial for the sprouting and 
growth of the lymphatic vasculature but not for its induction [111]. Interestingly, 
Vegfc+/! mice are viable but develop lymphoedema, suggesting that both 
Vegfc alleles are needed to provide the dose required for the correct 
establishment and function of the lymphatic vasculature [111]. 
Contrary to Vegfc!/! mutants, Figf!/! deficient mice are healthy and fertile, 
without any severe lymphatic deficiency, presenting only a small reduction in 
the number of lymphatic capillaries surrounding the bronchioles in the lungs, 
where FIGF expression is usually elevated [112]. These results suggested a 
minor role for FIGF in lymphatic development or that the lack of FIGF is 
compensated by VEGFC [112]. 
3.2.4. VEGFE AND SVVEGF 
VEGFE is the generic name of a subfamily of VEGF-related proteins encoded 
in the genome of the strains NZ-7, NZ-2 [113], D1701 [114] and NZ-10 [115] of 
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Orf virus. VEGFE seems to contribute to the enormous capillary proliferation 
and dilation in skin lesions observed upon viral infection [113,116]. Another 
VEGF-related protein (VEGFEVR634) was isolated from the Pseudocowpox 
virus, a distant species of the Parapoxvirus genus [115]. Interestingly, VEGFE 
family members share only 20 to 25% amino acid identity with VEGFA and do 
not contain a heparin-binding domain [113,117]. However, VEGFE induces a 
potent mitogenic activity on ECs in vitro and mice engineered to express 
VegfeNZ7 under the control of the skin K-14 promoter showed enhanced 
angiogenesis in subcutaneous tissue without side effects [118]. The VEGFE 
family members are selective ligands for VEGFR2 [114,115,116,118,119]. 
VEGFENZ2 [119] and VEGFENZ10 [115] were reported to bind also NRP1. 
VEGF-related proteins have also been identified in the snake venom of 
different species and generically designated as svVEGFs [120,121,122]. The 
cysteine knot motif is conserved in these proteins but the biological affinities 
for the VEGFRs differ, despite sharing a 50% homology with VEGFA165 [72]. 
3.3. VEGF RECEPTORS 
The biological effects of the VEGFs are mediated through the binding and 
activation of two related members of the RTK superfamily: VEGFR1 (also 
named as fms-like tyrosine kinase 1, FLT1) and VEGFR2 (also referred to as 
kinase insert domain, KDR). A third member of this receptor family, VEGFR3 
(also named as fms-like tyrosine kinase 4, FLT4), binds VEGFC and FIGF and 
is primarily involved in the lymphatic vessel development and 
lymphangiogenesis [71]. Genetic ablation of Vegfr3 in mice (Vegfr3!/!) leads to 
embryonic death between E9.5-14 due to fluid accumulation in the pericardial 
cavity and cardiovascular failure [123]. Both vasculogenesis and angiogenesis 
occur in these embryos. However, defects in vascular remodelling were 
observed, suggesting that VEGFR3 is not involved in initial steps of the 
vascular assembly, but rather in the remodelling of the vascular plexus [123]. 
These effects could also be due to increased availability of VEGFC and FIGF 
for activation of VEGFR2 [124]. In the adult VEGFR3 expression is almost 
GENERAL INTRODUCTION 
 
 24 
restricted to lymphatic vessels and it is in the lymphatic vasculature 
development and lymphangiogenesis that VEGFR3 has a central role [38].  
A different class of VEGF receptors are the neuropilins, NRP1 and NRP2, 
initially described as mediators of neuronal guidance, which are also involved 
in angiogenesis [125]. Neuropilins are single-pass transmembrane non-
tyrosine kinase proteins with a large extracellular domain and a short 
cytoplasmic domain [125]. Neuropilins are co-receptors for both the 
semaphorin family of axonal guidance molecules and the VEGF family [125]. 
The co-expression of NRP1 and VEGFR2 in porcine aortic ECs enhanced the 
binding and bioactivity of VEGFA165, suggesting that NRP1 acts as a co-
receptor for VEGFR2 [126]. Genetic studies have shown that Nrp1!/! knockout 
mice die at E13 from cardiovascular defects and deficient neural 
vascularization [127]. Also, mice overexpressing NRP1 die in utero at E17.5 
due to cardiac defects and excessive and hemorrhagic blood vessels [128]. 
Nrp2!/! knockout mice are viable and show a normal vascular phenotype [129]. 
However, double knockout mice (Nrp1!/!Nrp2!/!) die in utero at E8.5 and show 
a severe vascular phenotype with greatly diminished yolk sac vasculature and 
disorganized blood vessels, resembling the Vegfa!/! and Vegfr2!/! knockout 
mice [130]. These genetic studies thus demonstrated a partial genetic 
redundancy between NRP1 and NRP2, and support an essential role for 
neuropilins in VEGF signaling [125]. 
Structurally, the VEGF receptor-protein tyrosine kinases consist of an 
extracellular region containing seven immunoglobulin (Ig)-like domains (in 
VEGFR3 the fifth Ig-like domain is substituted by a disulfide bridge); a single 
transmembrane region; a juxtamembrane domain; a split tyrosine kinase 
domain, that is interrupted by a 70-amino acid kinase insert, and a C-terminal 
tail [75], (Figure 5).  
Classically, as for other RTKs, binding of VEGF to the extracellular domain of 
the transmembrane VEGFR leads to receptor dimerization, trans 
autophosphorylation and protein kinase activation [75].  
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Figure 5. Squematic structure of the VEGF receptors. 
The structure of VEGFRs is composed of an extracellular region with Ig-like domains; a single 
transmembrane domain and an intracellular domain comprising a kinase domain split by a kinase insert 
and a C-terminal tail. Adapted from [71,75]. 
The intracellular recruitment of adaptors and second messengers activates 
complex signaling cascades leading to the modulation of a variety of cellular 
functions, such as vascular permeability, migration, proliferation and survival 
[75]. Upon VEGFR activation by VEGF, ECs activate the angiogenic program 
[75]. 
3.3.1. VEGFR1 – A DUAL FUNCTION RECEPTOR 
VEGFR1 was cloned and characterized from a human placenta cDNA library 
[131] and was the first high affinity VEGF receptor to be identified [132]. 
Human VEGFR1 gene encodes a 1338 amino acids protein of 180 kDa [131]. 
Structural and mutational experiments have identified the second Ig-like 
domain as the VEGFA, PlGF and VEGFB binding site and the first Ig-like 
domain as a receptor dimerization motif [133].  
The binding affinity of VEGFR1 for VEGFA is at least 10 fold higher than that 
of VEGFR2 (dissociation constant Kd=10 pM), [62]. However, despite binding 
GENERAL INTRODUCTION 
 
 26 
VEGF with high affinity, VEGFR1 presents weak tyrosine kinase 
phosphorylation activity following VEGF stimulation [62]. Gene-targeting 
studies demonstrated the essential role of VEGFR1 in vascular development. 
Vegfr1!/! mice die in utero between E8.5-9.0 exhibiting a severe 
disorganization of the vasculature and an increased number of ECs [11]. The 
phenotype observed was due to an increased mesenchymal to hemangioblast 
commitment resulting in an excess of the EC population that leads to the 
development of a disorganized vascular plexus [134]. Based on the 
biochemical and genetic data it was proposed that VEGFR1 could be a 
negative regulator of the VEGF activity, acting as a “decoy” receptor to 
sequester VEGF, thus rendering it less available for interacting with VEGFR2 
[72]. Further genetic studies supported this idea since VEGFR1 tyrosine 
kinase (TK)-deficient mice (Vegfr1TK!/!) are viable and fertile and do not exhibit 
deficiencies in vascular development, indicating that the VEGFR1 TK activity 
is dispensable for embryonic angiogenesis and that the extracellular domain of 
VEGFR1 is sufficient to rescue lethality in Vegfr1 null mutant mice [135].  
Alternative splicing generates a soluble truncated form of the VEGFR1 that 
encodes only the first six Ig-like domains of the extracellular region of the 
receptor [72]. sVEGFR1 binds VEGF strongly and efficiently blocks the VEGF-
activity when present in a 10 fold excess over VEGF [136]. High sVEGFR1 
levels are expressed in the placenta, where it might control VEGF activity at 
particular stages of pregnancy [136]. Interestingly, 50% of the mice expressing 
exclusively the extracellular region of VEGFR1 (Vegfr1(TM-TK)!/!) die in utero at 
E8.5 due to poor blood vessels development, suggesting that the VEGFR1 
transmembrane domain (TM) is important for maintaining the ligand-binding 
domain attached to the cell membrane and directly regulate the levels of 
ligands near the cell surface [137]. 
3.3.1.1. SIGNAL TRANSDUCTION  
Despite the proposed negative regulation of the VEGF activity, other studies 
suggest a positive role for VEGFR1 signaling. VEGFR1 overexpression in 
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porcine EC induces a moderate increase in the VEGFR1 TK activity [138]. In 
these conditions, biochemical experiments identified six potential tyrosine 
phosphorylation sites in the C-terminal tail of VEGFR1 (Figure 6): Y1169; 
Y1213; Y1242; Y309; Y1327 and Y1333.  
 
 
Figure 6. Schematic structure of VEGFR1 
The extracellular domain, with the seven Ig-like structures, binds VEGF and PlGF and is involved in the 
regulation of the EC number during development by acting as a “decoy receptor” as explained in the 
text. Residues Y1069, Y1213, Y1242, Y1309, Y1323 and Y1333 were identified in the C-terminal tail. 
VEGF induces phosphorylation (P) of Y1213 and PlGF induces phoshorylation (P) of Y1309. Three 
SH2-domain containing molecules bind to PY1213: SHP-2, PLC"1 and Grb2. The intracellular signaling 
of VEGFR1 is primarily involved in the monocyte migration and regulation of haematopoiesis and 
enhances angiogenesis through intra- and intermolecular phosphorylation of VEGFR2 as explained in 
the main text. Adapted from [71, 139]. 
Tyrosine residue Y1213, was identified as docking site for three                   
Src homology 2 domain (SH2)-binding proteins namely SHP-2, phospholipase 
C ! (PLC!) and growth factor receptor-bound 2 (Grb2) [136,138]. Consistently, 
increased tyrosine phosphorylation of PLC! was observed in VEGFA- 
stimulated porcine aortic EC overexpressing VEGFR1 [136]. A specific 
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biological response that requires the VEGFR1 TK activation is the migration of 
monocytes in response to VEGF and PlGF as Vegfr1TK!/! mice shows 
defective mobilization of monocytes [57]. Consistent with this, the 
monocyte/macrophage lineage expresses high levels of VEGFR1, but not 
VEGFR2, suggesting the involvement of VEGFR1 in the VEGF-dependent 
signaling [62]. 
In monocytes, it was shown that activation of VEGFR1 through PlGF results in 
the activation of the PI3-kinase (PI3K)/AKT and Erk-1/2 pathways leading to 
chemotaxis and to the production of several inflammatory cytokines [140]. 
Also, activation of VEGFR1 by PlGF is involved in the recruitment of VEGFR1-
positive hematopoietic progenitor cells (HPCs) from the bone marrow [141]. 
These VEGFR1+HPCs cells and other accessory cells released from the bone 
marrow can create a favorable microenvironment for cancer cell spreading 
[142,143]. The migration and influx of these activated VEGFR1+HPCs to 
distant tissues induces early changes in the local microenvironment, termed 
the “pre-metastatic niche”, priming the tissues for tumor cell implantation and 
proliferation [142,143]. These VEGFR1+HPCs clusters preserve the 
expression of primitive cell surface markers, rather than undergoing lineage-
committed maturation. The recruitment of VEGFR1+HPCs might establish the 
metastatic signature, determining the tumor-pattern of metastatic spread and 
contributing for cancer cell proliferation [142,143]. 
Although VEGF and PlGF bind equally to VEGFR1 each activates VEGFR1 in 
a distinct manner. For instance, VEGFA stimulates VEGFR1 Y1213 
phosphorylation whereas PlGF stimulates Y1309 phosphorylation [57]. PlGF 
binding, but not VEGF is able to alter the gene expression profile in mouse 
capillary ECs. It was shown in vivo that PlGF can enhance VEGFA-mediated 
angiogenesis in ischemic conditions [101], through a molecular process of 
crosstalk between the two VEGF receptors [57]. 
In the absence of PlGF, VEGFR1 acts as a “reservoir” for VEGF regulating the 
availability of VEGF for binding VEGFR2 [57]. When PlGF binds and activates 
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VEGFR1, potentiates angiogenesis through different mechanisms: 1) VEGF is 
displaced from VEGFR1 and becomes more available to bind and activate 
VEGFR2; 2) PlGF-mediated VEGFR1 activation leads to intermolecular trans-
phosphorylation of VEGFR2, increasing VEGFR2 phosphorylation; this 
mechanism requires VEGFR1 TK signaling, since the increased 
phosphorylation levels of VEGFR2 were not observed in Vegfr1TK!/! cells;      
3) Another crosstalk mechanism is observed in VEGFR1/VEGFR2 
heterodimers, where the trans-phosphorylation occurs intermolecularly 
induced either by PlGF/VEGF heterodimers or VEGF homodimers [57]. 
Together these data suggest an important regulatory role for VEGFR1 in 
VEGF and PlGF mediated angiogenesis, specially potentiated in pathological 
conditions such as cancer [57]. 
3.3.2. VEGFR2 – A PRO-ANGIOGENIC RECEPTOR 
The human VEGFR2 gene encodes a 200-230 kDa protein with 1356 amino 
acids. Mutation analyses of the VEGFR2 extracellular domain have shown that 
the second and third Ig-like domains were high affinity VEGF binding sites and 
that the first and fourth Ig-like domains were important for the receptor 
dimerization [144]. The fifth and sixth Ig-like domains of VEGFR2 seem to be 
important to preserve ligand binding [145]. Both VEGFR1 and VEGFR2 
undergo post-translational modifications. In the case of VEGFR2, but not 
VEGFR1, only the glycosylated or mature form of the receptor is efficiently 
autophosphorylated upon ligand binding [70]. 
VEGFR2 binds to VEGF with a lower affinity than VEGFR1 (Kd=75 pM), but in 
contrast to VEGFR1 it has high tyrosine kinase activity [62]. 
Knockout Vegfr2!/! embryos die in utero between E8.5-9.0 as a result of 
profound defects in vasculogenesis and angiogenesis. Vegfr2!/! embryos fail 
to develop yolk-sac blood islands and organized blood vessels and show a 
reduced number of hematopoietic and EC precursors [12]. These results 
suggested a pivotal role for VEGFR2 in vascular development and therefore it 
is considered the major mediator of the VEGF signaling during vasculogenesis 
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and angiogenesis [62]. The critical role of VEGFR2 in these processes led to 
the intense scrutiny of the signaling cascades mediated by its activation and 
that will be further discussed in the next section. 
3.3.2.1. SIGNAL TRANSDUCTION 
Several tyrosine residues in the intracellular region of VEGFR2 were identified, 
using different systems and shown to be autophosphorylated upon ligand 
binding: Y951 and Y996 in the insert kinase domain; Y1054 and Y1059 in the 
kinase domain 2 [146]; Y1075 and Y1214 in the C-terminal tail [147,148]. 
Phosphorylated Y1305, Y1309 and Y1319 in the C-terminal tail have also 
been reported [149]. Phosphorylated VEGFR2-tyrosine residues serve as 
docking sites for molecules that initiate different signaling cascades leading to 
cellular responses such as proliferation, migration, survival and permeability 
[75]. The relative contribution of the different phosphorylated tyrosine residues 
for the VEGFR2 function in vivo is still largely unknown. Genetic studies have 
shown that mice carrying a Vegfr2 tyrosine (Y) to phenylalanine (F) Y1173F 
mutation (Y1175, in human), (Vegfr2Y1173F) die around E8.5-9.0 with a similar 
phenotype to that observed in Vegfr2!/! embryos. Additionally, mice 
exclusively expressing Vegfr2Y1212F mutation (equivalent to human Y1214) are 
viable and fertile. These studies suggested that the activation of Y1175, but 
not Y1214 is critical for the VEGF-mediated actions in vivo [150]. Several in 
vitro studies have described some of the molecular cascades that can be 
initiated upon VEGFR2 activation (Figure 7).  
The phosphorylation of Y1054 and Y1059 is required for maximal kinase 
activity [151]. VEGFR2 phosphorylated on Y1175 binds to and activates PLC!, 
which mediates the activation of the extracellular regulated kinase (Erk) 
pathway leading to cell proliferation [71], (Figure 7).  
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Figure 7. VEGFR2 schematic structure and signal transduction.  
The schematic structure of the VEGFR2 is identical as shown before for VEGFR1. The extracellular 
domain, binds VEGFA, processed (p) VEGFC, FIGF, VEGFE and svVEGF. Several intracellular 
proteins bind to specific phosphorylated (P) tyrosine residues in the intracellular region of VEGFR2, via 
their SH2 domains, leading to the phosphorylation and activation of these proteins. PY1175 binds 
PLC!, which by hydrolysis generates second messenger DAG and leads to the release of intracellular 
calcium (Ca2+). DAG is a physiological activator of PKC that in turn activates the Raf-MEK-Erk pathway 
leading to cell proliferation. The activation of Ras via VEGFR2 is unclear. PKC also activates eNOS 
that induces the NO production and therefore increases permeability. TSAd binds to PY951 and Src 
inducing cell migration. TSAd can also activate PI3K-dependent migration, however is not clear if this 
pathway is activated in EC. Binding of Shb to PY1175 regulates activation PI3K and the AKT/PKB 
survival pathway. AKT can also induce permeability by activation of eNOS. PY1214 results in activation 
p38 MAPK and HSP27 leading to actin remodelling and cell migration. The activation of FAK and 
paxilin is also mediated by VEGFR2 activation and regulates the focal adhesion turnover and cell 
migration, however is not clear the specific tyrosine involved. Adapted from [71]. 
VEGF activation of VEGFR2 also induces cell survival. This effect seems to be 
mediated by binding of the adapter Src homology 2 domain (Shb) to Y1175, 
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which then activates PI3K, leading to the downstream activation of protein 
kinase B PKB/Akt that mediates cell survival [71].  
Another important EC response to VEGF is the activation of signaling 
pathways leading to cell migration, mediated by VEGFR2. This effect seems to 
be mediated by the binding of the T-cell-specific adapter (TSAd), a VEGF 
receptor-associated protein, to phosphorylated Y951 and its activation, which 
promotes its association with Src leading to actin reorganization and cell 
migration [149], (Figure 7). Additionally, TSAd binds PI3K that can also be 
involved in cell migration [152]. The activation of PI3K-AKT also leads to the 
activation of endothelial nitric oxide synthase (eNOS), inducing the production 
of nitric oxide (NO) and thereby increasing the vascular permeability [71]. 
Interestingly, the phosphorylation levels of Y951 were found to be increased in 
embryonic bodies (EB) sprouting vessels but not in EB resting vessels, further 
suggesting a role for Y951 in VEGFA dependent migration [149]. 
Phosphorylation of Y1214 was shown to activate p38 MAPK resulting in the 
phosphorylation of the heat-shock protein-27 (HSP27) a chaperone that 
positively regulates VEGF-induced actin remodeling and motility [71],      
(Figure 7). The VEGFR2-mediated activation of Focal adhesion kinase (FAK) 
and paxilin, involved in the regulation of the focal adhesion turnover have also 
been implicated in VEGF/VEGFR2-induced migration. Although is not clear 
which VEGFR2 tyrosine residue is involved in this activation [71]. 
3.3.2.2. REGULATION OF THE VEGFR2 GENE EXPRESSION 
VEGFR2 is the earliest marker of mesodermal vascular precursors in mice [8]. 
VEGFR2 is strongly and specifically expressed in vascular ECs, although it 
has been observed in other cell types, such as retinal progenitor cells, 
neurons, osteoblasts, pancreatic duct cells and megakaryocytes [62]. The 
human VEGFR2 gene promoter shows a class II promoter structure: it does 
not have a TATA box region but is highly complex containing multiple 
regulatory elements [153], (Figure 8).  
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Figure 8. Schematic structure of the human VEGFR2 promoter.  
Several consensus-binding sequences for the indicated transcription factors were predicted from the 
human VEGFR2 promoter sequence between -300/+268 bp relative to the transcription start site 
(indicated with black arrow). Adapted from [153]. 
The cloning and functional analysis of the human VEGFR2 gene promoter 
identified a fragment from -225 to +268 base pairs (bp) relative to the 
transcription start site as required for maximal promoter activity [153,154]. This 
segment, defined as the core promoter for human VEGFR2 gene, contains 
putative binding sites for the transcription factors AP-2, NF%B, and Sp1. Also, 
GATA elements and E-Box sequences have been identified in this region 
[153,154], (Figure 8). 
Studies using electrophoretic mobility shift assays (EMSA) and in vitro DNase 
I footprinting have shown that the transcription factor specificity protein 1 (Sp1) 
binds to five CG-rich regions of the human VEGFR2 promoter in ECs but not 
in other cell types, suggesting that this element is essential for the specific 
VEGFR2 expression in ECs [154]. Different studies also showed that binding 
of Sp1 to the GC-region (-79 to -68) enhanced VEGFR2 expression while 
binding of Sp3 to the same region attenuated this response [155]. 
Sp1 is a ubiquitous transcription factor that binds to GC-rich regions in gene 
promoters and was initially implicated in the regulation of housekeeping genes 
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[156]. Interestingly, the Sp1 gene is auto-regulated and is highly expressed in 
the heart of mouse embryos [156], suggesting an important role for this 
transcription factor in the regulation of the vasculature. Sp1 has also been 
implicated in the regulation of the VEGF gene [90]. Additionally, hormone-
induced activation of the VEGFR2 promoter has also been reported to be 
dependent of Sp proteins [157].  
Other mechanisms such as epigenetic regulation might also contribute to the 
VEGFR2 expression [158]. Interestingly, a hypoxia responsive element (HRE) 
was not identified in the human VEGFR2 gene promoter, indicating that unlike 
VEGF and VEGFR1, VEGFR2 transcription is not directly regulated by 
hypoxia [159].  
3.3.2.3. INTRACELLULAR TRAFFICKING 
VEGFR2 intracellular trafficking is potentially an important mechanism through 
which angiogenesis and other endothelial functions can be regulated, in 
addition to the previously described signaling from cell surface-located 
receptors. Although the signal transduction activated by VEGFR2 upon VEGF 
stimulation has been the object of intense study, the mechanisms mediating 
the endocytosis and membrane trafficking of VEGFR2 are still poorly 
understood.  
The majority of the data available on RTK trafficking is based on the epidermal 
growth factor receptor (EGFR) and its ligand epidermal growth factor (EGF) 
[160]. Until recently RTK internalization was thought to be exclusively for 
downregulation of receptor activity through degradation. In the absence of 
ligand stimulation, EGFR resides largely at the cell surface. Upon EGF 
binding, soluble clathrin is recruited to the cell membrane to form clathrin-
coated membrane invaginations surrounding the activated receptor and trigger 
an endocytosis process to sort EGFR into early endosomes. From early-
endosomes EGFR can either be recycled from this compartment back to the 
plasma membrane or under ligand saturation conditions the receptor 
undergoes degradation through late endosomal sorting to the lysosome [160]. 
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Therefore, initially RTK internalization was considered an important 
mechanism to control the intensity and duration of the signal transduction 
[160]. 
Two studies on VEGFR2 trafficking suggested that VEGFR2 is ubiquitylated 
by the E3 ubiquitin ligase, c-Cbl [161,162]. However, a third study suggested 
that activated PKC, but not c-Cbl, marks the receptor for internalization and 
degradation [163]. Despite the leading idea of the receptor internalization for 
degradation to stop the signaling process, increasing evidence suggests that 
receptor activity may be sustained on endosomes [164,165]. It has been 
shown that cell confluency inhibits EC growth and proliferation, in a process 
mediated by increased cell-cell junctions [164]. These adherens junctions are 
modulated by a class of adhesive transmembrane proteins called cadherins 
localized at the intercellular junctions forming zipper-like structures once cells 
get in contact. ECs express a cell-specific cadherin called vascular endothelial 
cadherin (VE-cadherin or VEC) that forms a complex with VEGFR2 and 
inhibits its phosphorylation and mitogen activity. It was described that in the 
absence of VE-cadherin, VEGFR2 is rapidly internalized to endosomes via a 
clathrin-dependent pathway, maintaining its signaling activity rather than being 
degraded [164]. The internalization of VEGFR2 and sustained receptor 
signaling was recently shown to be required for VEGF-induced tip cell 
filopodial extension [165]. EphrinB2 at the tip cell filopodia was shown to 
regulate VEGFR2 endocytosis and intracellular signal to direct filopodial 
extension in vivo [165].  
Other studies have shown that activated VEGFR2 is internalized preferentially 
via a caveolar pathway and transported to perinuclear caveosomes, 
colocalizing with caveolin-1 [166]. Caveolae are lipid raft-enriched, flask-
shaped invaginations, present in the plasma membrane of different cell types 
especially in ECs and adipocytes [167,168]. Caveosomes are intracellular 
caveolin-1-containing membrane-bounded structures of neutral pH, distinct 
from classical low pH endosomal compartments [167,169]. The VEGFR2, 
caveolin-1 interaction has been reported at the plasma membrane level and 
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caveolin-1 was suggested to act as a negative regulator of VEGFR2 activity in 
resting conditions [170]. However, in the presence of VEGF, the localization 
within caveolae domains is important for the VEGF-induced phosphorylation of 
VEGFR2 [170]. Importantly, removal of VEGFR2 from caveolae domains at 
cell surface results in inhibition of EC migration [170]. A similar effect was 
observed in caveolin-1 knockout mice (Cav!/!), [171,172]. A defective post-
ischemic neo-vessel formation due to a failure in VEGFR2 
compartmentalization in caveolae domains was reported [171].  
Other proteins were also shown to be involved in the correct positioning of 
VEGF-VEGFR2 in caveolae vesicles, such as dynamin-2 [173]. The reported 
perinuclear colocalization of caveolin-1, dynamin-2, and VEGFR2 suggests 
that these three components are in a complex probably located in the trans-
Golgi region [173]. Dynamin-2 mutants induced an enhanced VEGFR2 
degradation by lysosomal and proteasomal proteases since VEGFR2 failed to 
localize in caveosomes [173,174]. Also, it was reported that dynamin-2 
inhibitors abolished the VEGF-induced internalization of VEGFR2, resulting in 
decreased tip cell filopodial extensions [165]. From caveosomes the 
internalized cargo can be delivered to the endoplasmic reticulum through 
different pathways or possibly undergo a retrograde transport pathway to the 
nucleus [160]. This last idea is particularly interesting considering recent 
publications reporting the presence of VEGF or phosphorylated VEGFR2 in 
the nucleus of a large number of cell types in a variety of physiological and 
pathological conditions. For instance, nuclear VEGFR2 was observed in 
normal and neoplastic renal tissues [175,176], in the nucleus of MCF-7, HeLa 
and HL60 cells [176] and in bovine and rat ECs [166,177]. A similar finding 
was reported in another study showing that VEGFR2 is constitutively 
phosphorylated and located in the nucleus of VEGF-producing leukemias [60].  
The mechanisms regulating VEGFR2 intracellular trafficking towards the cell 
nucleus are not known and will be one of the focuses of this thesis. 
Furthermore, the nuclear localization of VEGFR2 opens the possibility of its 
direct involvement in transcriptional regulatory activities. 
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4. AIM OF THIS THESIS 
The aim of this work is to study the molecular mechanisms and relevance 
of the nuclear internalization of VEGF and VEGFR2 in ECs. Until recently, 
VEGFR2 was described as a tyrosine kinase membrane receptor. In this 
work, I focused on the molecular mechanisms underlying the VEGFR2 
nuclear translocation in ECs. Furthermore, I investigated the role of 
VEGFR2 as a nuclear protein and defined the basis for a novel function for 
VEGFR2 in the transcriptional regulation of its own expression. 
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2.1. OVERVIEW OF THE ARTICLE: 
VEGF and VEGFR2 (KDR) Internalization is Required for Endothelial 
Recovery during Wound Healing  
Susana Constantino Rosa Santos, Cláudia Miguel, Inês Domingues, Ângelo 
Calado, Zhenping Zhu, Yan Wu and Sérgio Dias.  
Exp Cell Res. 2007 May 1;313(8):1561-74.  
PMID: 17382929 
The angiogenic growth of new blood vessels is crucial during embryonic 
development and in adult tissues in different physiological and pathological 
situations such as wound healing or tumor growth, among others. Endothelial 
cells (ECs) lining the inside of all blood vessels are key components in the 
angiogenic process. Following injury, quiescent vascular ECs are reactivated 
in response to different stimuli. ECs migrate and proliferate towards the wound 
bed inducing tissue vascularization and contributing to the healing process. 
Vascular Endothelial Growth Factor (VEGF) is one of the most important pro-
angiogenic factors. VEGF is produced in tissues in response to hypoxia and 
binds its receptors VEGFR1 and VEGFR2 at the EC surface. The molecular 
processes triggered upon VEGF activation of its receptors are extremely 
important and have been the focus of intense work. Although VEGFR2 has a 
lower affinity for VEGF than VEGFR1, it is the major mediator of the mitogenic 
activity induced by VEGF in ECs. VEGFR1, despite its higher affinity for 
VEGF, has a weaker kinase activity and until recently, it was thought to act 
mainly as a “decoy” receptor for VEGF in ECs. However, it was demonstrated 
that VEGFR1 activation leads to intermolecular trans-phosphorylation of 
VEGFR2, increasing VEGFR2 phosphorylation and activation. 
In this paper, we demonstrated that VEGF and VEGFR2 are translocated to 
the EC nucleus in a process mediated by VEGFR1 and that this internalization 
is required for EC recovery following in vitro wounding. 
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- We showed that, upon VEGF stimulation, VEGF and VEGFR2 
translocate to the nucleus of ECs. A neutralizing antibody against 
VEGFR1 (6.12 Ab) blocked the VEGF-VEGFR2 nuclear accumulation, 
showing a functional relevance for the receptors’ crosstalk.  
- We also demonstrated that VEGFR2 internalization is blocked by 
drugs inhibiting its phosphorylation (KDRi). Additionally, VEGFR2 
tyrosine deletion mutants showed impaired nuclear accumulation 
further supporting that the phosphorylation of VEGFR2 is important for 
its nuclear translocation.  
- We explored the VEGF-VEGFR2 internalization process and showed 
that it requires the activation of the PI3K pathway and is linked to a 
caveolae-mediated endocytic pathway, via microtubules.  
- The functional relevance of the VEGF and VEGFR2 nuclear 
translocation was supported by wound healing assays in vitro. The 
blockage of the VEGFR1-mediated VEGF-VEGFR2 nuclear 
translocation led to a delayed EC recovery following injury.  
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2.3. SUPPLEMENTARY RESULTS 
VEGF AND VEGFR2 NUCLEAR TRANSLOCATION IS MEDIATED BY THE NUCLEAR 
PORE COMPLEX 
We further investigated the nuclear translocation process of   VEGF/VEGFR2 
in ECs. We treated ECs with a lectin, wheat germ agglutinin (WGA), which 
inhibits the nuclear protein transport and interacts directly with the nuclear 
pore complex. We observed by confocal microscopy the accumulation of 
VEGF and VEGFR2 in the cytoplasmic face of the nuclear pore envelope in 
cells treated with WGA (Figure S1) suggesting, that the internalization of this 
complex ultimately results in the transport to the cell nucleus, via the nuclear 
pore complex.  
 
Figure S1. VEGF and VEGFR2 are transported to the nucleus via the nuclear pore complex. 
ECs were cultured in growing medium and left untreated or treated with WGA at the indicated 
concentrations. These cells were stained with a rabbit anti-human VEGFR2 (I) antibody (Alexa 594) 
and DAPI (blue). Cytoplasmic accumulations of VEGFR2 are indicated with white arrows (upper panel). 
A similar experiment was performed for VEGF and ECs were stained with a mouse anti-human VEGF 
antibody (Alexa 488) and DAPI (blue). Cytoplasmic accumulations of VEGF are indicated with white 
arrows (lower panel) Scale bar 10 µm. 
The presence of nuclear localization signals (NLS) in the VEGFR2 sequence 
were neither described in the literature nor identified in bioinformatics analysis 
performed by us (data not shown). Interestingly, five potential NLS sequences 
were identified in the C-terminal region of VEGF [1]. We can then speculate 
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that the recognition of the VEGF NLS signal is implicated in the nuclear 
trafficking of the VEGF/VEGFR2, via the nuclear pore complex.  
Taken together, the results presented here indicate that VEGF and VEGFR2 
are actively transported to the cell nucleus, suggesting a biological function for 
the internalization of VEGF/VEGFR2. 
Our results also showed that the VEGF-VEGFR2 nuclear internalization is a 
dynamic process suggesting that these proteins are also exported back to the 
cytoplasm/cell surface. Therefore, we analyzed the nucleo-cytoplasmic 
translocation of VEGF and VEGFR2 by treating ECs with Leptomycin B, a 
nuclear export inhibitor (Figure S2).  
By immunofluorescence, we observed that VEGF, but not VEGFR2, 
accumulated in the nucleus of ECs treated with increasing concentrations of 
Leptomycin B for 1 hour (Figure S2). 
 
Figure S2. VEGF accumulates in the nucleus after treatment with Leptomycin B. 
ECs were cultured in growing medium and left untreated or treated with leptomycin B at the indicated 
concentrations, for 1 h. Immunofluorescence analysis with a rabbit anti-human VEGFR2 (I) antibody 
(Alexa 594) and DAPI (blue), (upper panel). A similar experiment was performed for VEGF and ECs 
were stained with a mouse anti-human VEGF antibody (Alexa 488) and DAPI (blue). Note the VEGF 
nuclear accumulation in ECs treated with 10 and 20 µM Leptomycin B, (lower panel). Scale bar 20 µm. 
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These results suggest that VEGF, but not VEGFR2, is exported from the 
nucleus by a process inhibited by leptomycin B, suggesting the involvement of 
a nuclear export signal (NES)-dependent mechanism. 
VEGFR2 INTERNALIZATION DOES NOT INVOLVE RECEPTOR DEGRADATION 
We could not exclude the possibility that the endocytosis of VEGF/VEGFR2 
might be involved in the downregulation of the receptor at the cell surface 
resulting in the attenuation of the signal mediated by VEGF-VEGFR2. It was 
described that c-Cbl is involved in the downregulation of several RTKs, upon 
recruitment to specific autophosphorylated forms of these receptors enhancing 
their degradation through ubiquitylation [2]. Regarding VEGFR2 there is no 
consensus for the involvement of c-Cbl in the process of endocytosis and 
degradation of the receptor [3,4]. In order to investigate the involvement of c-
Cbl in the degradation of VEGFR2 in ECs, we analyzed the interaction of 
these proteins in VEGFR2 whole cell immunoprecipitates by western-blot 
(Figure S3A).  
 
Figure S3. VEGFR2 does not interact with c-Cbl. 
(A) ECs were cultured in growing medium and whole protein extracts were prepared. 
Immunoprecipitation (IP) of whole cell lysates (W) was conducted with the anti-VEGFR2 (I), (lane 2) 
followed by western blotting using the anti- VEGFR2 (I) and anti-c-Cbl antibodies. VEGFR2 antibody 
plus beads (without W) was used as negative control for immunoprecipitation (lane 1). A control lysate 
was also included in the experiment (lane 3). (B) ECs were left unstimulated or stimulated with                 
20 ng/ml VEGF (upper panel) or 10 ng/ml PlGF (lower panel). VEGFR2 protein levels were analyzed by 
western blot in whole protein extracts obtained 1, 3 and 5 h upon stimulation.  
Under these experimental conditions, we failed to detect any interaction 
between VEGFR2 and c-Cbl (Figure S3A). Moreover, VEGFR2 protein levels 
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remained unchanged after 5 h of stimulation with VEGF (Figure S3B, upper 
panel) or PlGF (Figure S3B, lower panel). Together, the data presented here 
suggests that VEGFR2 is not degraded upon VEGF stimulation, but rather its 
nuclear internalization might be involved in new biological functions, such as 
gene transcription. 
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VEGFR2, Vascular Endothelial Growth Factor Receptor 2; VEGF, Vascular 
Endothelial Growth Factor; ECs, endothelial cells; FRAP, Fluorescence Recovery 
After Photobleaching; Y, amino acid tyrosine; F, amino acid phenylalanine.!
3.1. ABSTRACT 
The vascular endothelial growth factor (VEGF) is one of the most important 
pro-angiogenic factors. VEGF binds to the membrane receptor VEGFR2 that 
activates signaling cascades leading to cell proliferation, survival and 
migration. Previously, we showed that VEGF and VEGFR2 translocate to the 
endothelial cell (EC) nucleus and that this nuclear internalization is required for 
EC recovery during wound healing. We also showed that the VEGF-induced 
VEGFR2 internalization was impaired in VEGFR2 tyrosine deletion mutants 
suggesting that the activation/phosphorylation of the receptor is crucial for its 
nuclear translocation. In order to identify the tyrosine residues involved in the 
translocation of the receptor, we constructed several VEGFR2-GFP fusion 
proteins using the wild type (WT) or mutant forms of VEGFR2 in which one or 
more tyrosine residues were converted into phenylalanine, and tested their 
ability to be translocated to the nucleus in endothelial cells (ECs). Our 
preliminary results suggest that the tyrosine residue Y951 located in the 
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receptor kinase-insert domain is essential for the VEGFR2 nuclear 
internalization in ECs. 
3.2. INTRODUCTION 
Vascular Endothelial Growth Factor (VEGF) signaling through VEGF receptors 
(VEGFRs) is a crucial regulatory mechanism for vascular development and 
neovascularization in physiological and pathological processes [1]. VEGFA 
binds predominantly to two VEGF tyrosine kinase receptors VEGFR1 and 
VEGFR2 at the surface of vascular ECs [1]. Disruption of the Vegfr1 or Vegfr2 
genes in mice results in embryonic lethality due to obstruction of the vessels 
by an overgrowth of endothelial progenitors [2] or by a deficient development 
of endothelial and hematopoietic precursors [3], respectively. The VEGF 
receptors are members of the receptor tyrosine kinase (RTK) superfamily and 
consist of an extracellular domain comprising 7 Ig-like domains, a 
transmembrane domain, followed by an intracellular split tyrosine-kinase 
domain and a C-terminal tail [1]. VEGF has a higher affinity for VEGFR1 than 
for VEGFR2. However, the former receptor has a low kinase activity and a 
variety of studies suggest that it acts primarily as a “decoy” receptor for VEGF, 
regulating the availability of VEGF to VEGFR2 in developing blood vessels [4]. 
Therefore, the VEGF mitogenic effects are mediated through VEGFR2 in ECs. 
Dimerization of VEGFR2 upon VEGF-binding to its extracellular domain 
results in the autophosphorylation of tyrosine residues in its intracellular 
domain resulting in the activation of signaling pathways leading to proliferation, 
survival, permeability and migration [1]. Several autophosphorylation sites 
have been identified: Tyrosines Y951 and Y996 located in the kinase insert 
domain; tyrosines Y1054 and Y1059 in the kinase catalytic domain; tyrosines 
Y1175 and Y1214 in the C-terminal tail [1]. Tyrosine Y951 has been identified 
as a binding site for T-cell-specific adapter (TSAd), responsible for the 
cytoskeleton regulation and migratory responses of ECs to VEGFA [5,6]. 
Tyrosines Y1054 and Y1059 are involved in the positive regulation of the 
receptor kinase activity [7,8]. Phosphorylated tyrosine Y1175 (P-Y1175) binds 
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and activates phospholipase C! (PLC!) leading to the activation of the Erk 
pathway resulting in cell proliferation [9]. P-Y1175 also binds the adapter 
molecule Shb, activating the PI3K pathway and regulating cell survival [10].  
We have previously described that besides the classical signaling through the 
membrane receptor, there is a rapid nuclear internalization of VEGF and 
VEGFR2 in ECs, upon VEGF stimulation [11]. Furthermore, we have 
generated several VEGFR2 deletion mutants comprising different tyrosine 
residues and showed that VEGFR2 nuclear translocation requires the 
phosphorylation/activation of the receptor.  
Here, ECs were transduced with lentivirus expressing VEGFR2 WT or 
VEGFR2 tyrosine to phenylalanine double mutants. We analyzed the nuclear 
translocation dynamics of these mutants and our results showed that a sub-
population of the VEGFR2(Y951F/Y996F) mutant protein is immobilized in the 
cytoplasm and not translocated to the cell nucleus. The analysis of the 
translocation dynamics of the VEGFR2 tyrosine to phenylalanine single point 
mutants identified the tyrosine residue Y951 as the one required for the 
nuclear internalization of VEGFR2. 
3.3. RESULTS 
ESTABLISHMENT OF AN EC MODEL EXPRESSING VEGFR2 TYROSINE TO 
PHENYLALANINE POINT MUTANTS 
Our previously reported results suggested that activation/phosphorylation of 
VEGFR2 was important for its nuclear translocation (Chapter II, [11]). To 
further identify the tyrosine residues involved in the nuclear internalization of 
the receptor, we established an EC model of VEGFR2 overexpression fused 
to GFP (EC VEGFR2-GFP) using a lentiviral infection approach (Figure 1A). 
We generated two (tyrosine to phenylalanine) double mutants Y951F/Y996F 
(tyrosine residues in the kinase insert domain) and Y1054F/Y1059F (tyrosine 
residues in the kinase catalytic domain) fused to GFP (Figure 1A). 
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Figure 1. Establishment of an EC model expressing VEGFR2 tyrosine to phenylalanine point 
mutants. 
(A) Schematic representation of the cloning strategy in the lentiviral plasmid FUGW of VEGFR2 WT or 
tyrosine to phenylalanine mutants fused to GFP. (B) Live cell confocal imaging of EC VEGFR2-GFP 
(left panel), EC VEGFR2(Y951F/Y996F)-GFP (middle panel) and EC VEGFR2(Y1054F/Y1059F)-GFP 
(right panel). Lower panels show image detail of the cytoplasmic and nuclear distribution of the 
respective fusion protein VEGFR2-GFP. Scale bar 10 µm.  
To establish this model, the transduced cells were sorted to obtain a 100 % 
GFP positive population. 
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Since VEGFR2 activation is involved in the EC migration, we evaluated the 
migratory response of EC VEGFR2-GFP compared to control EC GFP 
(expressing only GFP) using an in vitro wound healing assay (Figure 2). 
 
Figure 2. VEGFR2 tyrosine to phenylalanine point mutants have a decreased migratory capacity. 
In vitro wound healing analysis of the migratory response of EC VEGFR2(Y951F/Y996F)-GFP and    
EC VEGFR2(Y1054F/Y1059F)-GFP compared to EC VEGFR2-GFP and control EC GFP (left panel) 
and % of wound recovery 7 h post-wounding (right panel). 
As expected, we observed that the wound recovery rate was higher in               
EC VEGFR2-GFP in comparison to control EC GFP (Figure 2), indicating that 
the VEGFR2 overexpression is correlated with a higher migratory phenotype.  
Furthermore, we also found that both EC VEGFR2(Y951F/Y996F)-GFP and 
EC VEGFR2(Y1054F/Y1059F)-GFP migrated less when compared to control 
EC VEGFR2-GFP (Figure 2). 
Next, the VEGFR2-GFP overexpression was analyzed by confocal microscopy 
(Figure 1B). As expected, VEGFR2-GFP is localized to the cell membrane and 
present both in the cytoplasm and in the nucleus of EC VEGFR2-GFP (Figure 
1B, left panel). Surprisingly, positive transduced EC VEGFR2(Y951F/Y996F)-
GFP and EC VEGFR2(Y0154F/Y1059F)-GFP showed a similar VEGFR2 
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expression pattern as EC VEGFR2-GFP, both in the cytoplasm and nucleus 
(Figure 1B, middle and right panel). 
Together, these results showed that EC VEGFR2(Y951F/Y996F)-GFP and  
EC VEGFR2(Y1054F/Y1059F)-GFP have a decreased migratory capacity 
although the VEGFR2 nuclear localization looked similar to EC VEGFR2-GFP.  
VEGFR2 (Y951F/Y996F) MUTANT HAS A SLOW NUCLEAR TURNOVER 
In order to study the nuclear translocation dynamics of the VEGFR2 WT and 
VEGFR2 tyrosine double point mutants, Fluorescence Recovery After 
Photobleaching (FRAP) analysis were performed. The GFP fluorescence was 
irreversibly bleached by a high intensity short laser pulse in the whole nuclear 
area (Figure 3A). The recovery of the fluorescence signal from the bleached 
area was measured every 5 s for 280 s and normalized to the initial intensity, 
after correcting for total bleaching loss and bleaching due to imaging. We 
compared the nuclear fluorescence recovery of EC VEGFR2(Y951F/Y996F)-
GFP and EC VEGFR2(Y1054F/Y1059F)-GFP to control EC VEGFR2-GFP 
(Figure 3B). In EC VEGFR2-GFP, the signal was fully recovered within 100 s 
(Figure 3A and 3B) suggesting a rapid turnover of VEGFR2-GFP between the 
cytoplasm and the nucleus. EC VEGFR2(Y1054F/Y1059F)-GFP showed a 
similar recovery kinetics as control EC VEGFR2-GFP (Figure 3B).  
However, EC VEGFR2(Y951F/Y996F)-GFP showed a much slower turnover 
rate, compared to EC VEGFR2-GFP and the normalized fluorescence 
intensity did not fully recover to the initial levels within 280 s (Figure 3B).  
These results indicate that at least a fraction of the mutant                
VEGFR2(Y951F/Y996F) population is immobilized in the cytoplasmic region 
and is not translocated to the nucleus. Interestingly, the steady state (i.e., 
before bleaching) nucleus/cytoplasm fluorescence ratio of the               
VEGFR2 (WT)-GFP and the two mutants is similar (Figure 3C) but the 
absolute values of intensity are not (Figure 3D) indicating that some mutations 
also have an effect on the expression levels of the mutant proteins. 
Taken together our results suggest that VEGFR2 tyrosine residues Y951 
and/or Y996 are involved in the VEGFR2 nuclear translocation. 
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Figure 3. VEGFR2(Y951F/Y996F)-GFP has a slow nuclear turnover. 
FRAP analysis of VEGFR2-GFP in EC VEGFR2-GFP and mutants EC VEGFR2(Y951F/Y996F)-GFP 
and EC VEGFR2(Y1054F/Y1059F)-GFP. (A, B) Live cells were imaged before and at defined time 
intervals after bleaching the entire nucleus. (A) The image sequence shows representative time points 
before, immediately after bleaching and 5, 15, 30, 50 and 100 s of fluorescence recovery of               
EC VEGFR2-GFP. White circles indicate the bleached region. (B) Fluorescence intensity in the 
bleached region was measured every 5 s for 280 s and normalized for the initial intensity. Results 
represent 3 independent experiments, with at least 10 different cells analyzed in each case. (C) Steady 
state (pre-bleach) nucleus/cytoplasm fluorescence intensity ratio measured for each cell pool. (D) 
Steady-state (pre-bleach) average intensity values of the indicated pools. Error bars represent standard 
deviation (SD). 
VEGFR2 TYROSINE RESIDUE Y951 IS REQUIRED FOR THE NUCLEAR 
TRANSLOCATION PROCESS 
To further evaluate the relative contribution of the tyrosine residues Y951 and 
Y996 to the VEGFR2 nuclear translocation, we performed a similar experiment 
with ECs expressing single mutants VEGFR2 Y951F or Y996F (Figure 4A).  
Interestingly, EC VEGFR2(Y951F)-GFP, but not EC VEGFR2(Y996F)-GFP 
showed a slower recovery rate, compared to EC VEGFR2-GFP (Figure 4C). 
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Figure 4. VEGFR2(Y951F)-GFP but not VEGFR2(Y996F)-GFP also has a slow nuclear turnover. 
(A) ECs expressing single mutants VEGFR2(Y951F)-GFP and VEGFR2(Y996F)-GFP were generated. 
(B) The image sequence shows representative time points before, immediately after bleaching and 5, 
15, 30, 50 and 100 s of fluorescence recovery of EC VEGFR2(Y951)-GFP. White circles indicate the 
bleached region. (C) FRAP analysis of EC VEGFR2-GFP, double mutant EC VEGFR2(Y951F/Y996F)-
GFP and single mutants EC VEGFR2(Y996F)-GFP and EC VEGFR2(Y951F)-GFP. Fluorescence 
intensity in the bleached nuclear region was measured every 5 s for 280 s and normalized for the initial 
intensity. Results represent 3 independent experiments with at least 10 different cells analyzed for each 
case. Error bars represent standard deviation (SD). 
As observed in EC VEGFR2(Y951F/Y996F)-GFP, the VEGFR2-GFP signal 
was not fully recovered within 280 s in EC VEGFR2(Y951F)-GFP (Figure 4B 
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and 4C). These results strongly suggest that the phosphorylation of the 
VEGFR2 tyrosine residue Y951 is required, if not sufficient, for the nuclear 
translocation of this receptor.  
3.4. DISCUSSION 
VEGF binding to the extracellular domain of VEGFR2 induces receptor 
dimerization and autophosphorylation of tyrosine residues located in its 
intracellular domain [12]. We have shown that the ligand-dependent activation 
is essential for the nuclear internalization of VEGF/VEGFR2 [11]. Additionally, 
we observed that VEGFR2 deletion mutants had a deficient nuclear 
translocation in a non-EC system [11] further supporting the model that 
phosphorylation is required for receptor internalization. In order to identify the 
tyrosine residues involved in this process, tyrosine to phenylalanine VEGFR2 
point mutants were constructed. EC transduced with lentivirus expressing 
VEGFR2 WT or mutants fused to GFP were generated. The four tyrosine 
residues Y951, Y996, Y1054 and Y1059 were primarily identified as 
autophosphorylation sites in the receptor intracellular domain after analysis of 
bacterially expressed VEGFR2 [13]. By performing an in vitro wound healing 
assay, we observed that EC VEGFR2(Y951F/Y996F)-GFP and                    
EC VEGFR2(Y1054F/Y1059F)-GFP had a lower migratory capacity compared 
to EC VEGFR2-GFP. Studies using mutant chimeras EGFR-VEGFR2 have 
shown that Y1059 is required for VEGF-induced proliferation, through the 
activation of MAPK pathway, but not migration [14]. Additionally, the 
autophosphorylation of the tyrosine residues Y1054 and Y1059, in the kinase 
catalytic domain, was described as critical for maximal receptor catalytic 
activity [7,8]. These data indicate that the cell effects mediated by tyrosine 
residues Y1054 and Y1059 are primarily associated with cell proliferation. 
However, our data with EC VEGFR2(Y1054F/Y1059F)-GFP suggest that 
these residues might also play a role in EC migration, since we observed a 
diminished migratory capacity compared to EC VEGFR2-GFP.  
An indirect effect, mediated by the lack of kinase activity might explain these 
apparently contradictory results, however further experiments are needed to 
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support this. A similar decrease in the EC migratory phenotype was observed 
in EC VEGFR2(Y951F/Y996F)-GFP, consistent with other studies that 
implicated Y951 in cell migration [5,14]. We took advantage of the      
VEGFR2-GFP fusion strategy to directly investigate the effect of these 
mutations in the nuclear internalization mechanism, by confocal microscopy. 
Previously, we observed that NIH 3T3 cells expressing VEGFR2 &1053-GFP 
deletion mutant showed a decreased VEGFR2 nuclear accumulation level and 
NIH 3T3 cells expressing VEGFR2 &950-GFP deletion mutant showed a clear 
absence of nuclear VEGFR2 [11]. In contrast, the tyrosine to phenylalanine 
mutants analyzed here showed the presence of VEGFR2-GFP both at cell 
surface and nucleus of ECs.  
As native VEGFR2 is present in ECs transduced with lentivirus expressing the 
different VEGFR2 mutant constructs a possible explanation for the common 
distribution pattern is that upon VEGF binding, “heterodimerization” between 
native and mutant VEGFR2 occurs. This could result in the nuclear 
translocation of the receptor observed even in cells expressing the VEGFR2 
tyrosine to phenylalanine mutants. This hypothesis is consistent with reports 
indicating that the binding properties of the VEGF ligands lead to the formation 
of both VEGFRs homodimers and heterodimers [15,16]. Testing this 
hypothesis would involve the analysis of the nuclear internalization dynamics 
of these mutants in an EC system with reduced or absent endogenous levels 
of native VEGFR2, such as in Porcine Aortic Endothelial Cells (PAEC). 
However, in these ECs, we would have to confirm the nuclear internalization of 
VEGFR2 and if it occurs, we would need to validate the molecular 
mechanisms previously found in our EC system.  
Since we have shown that VEGFR2 nuclear translocation is a dynamic 
process [11], we sought to analyze differences in the translocation kinetics of 
these VEGFR2 tyrosine mutants. We compared the fluorescence recovery 
rates after photobleaching of EC VEGFR2(Y951F/Y996F)-GFP, EC 
VEGFR2(Y1054F/Y1059F)-GFP and EC VEGFR2-GFP. Our results showed 
similar kinetics and recovery rates between EC VEGFR2(Y1054F/Y1059F)-
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GFP compared to EC VEGFR2-GFP. However, EC VEGFR2(Y951F/Y996F)-
GFP showed slower recovery kinetics and the fluorescent signal was not fully 
recovery in the time frame of the FRAP experiment (280 s). These results 
indicated that at least a fraction of the mutant VEGFR2(Y951F/Y996F)-GFP 
population was not internalized to the cell nucleus, suggesting that tyrosine 
residues Y951 and/or Y996 were involved in the nuclear translocation process.  
The FRAP analysis of EC expressing the single point mutants          
VEGFR2(Y951F)-GFP or VEGFR2(Y996F)-GFP revealed that                      
EC VEGFR2(Y951F)-GFP had a comparable slower recovery rate as 
observed for EC VEGFR2(Y951F/Y996F)-GFP, suggesting that the residue 
Y951, but not Y996, is essential for the nuclear translocation of the receptor. 
Interestingly, it was reported that the phosphorylation of Y951 is markedly 
observed in sprouting vessels, suggesting that the signal transduction 
dependent of the Y951 phosphorylation is required during angiogenesis [5]. 
These results are consistent with our previous observations that VEGF and 
VEGFR2 are rapidly internalized to the nucleus following injury in ECs facing 
the wounded area [11]. Another interesting aspect concerning signaling 
through phosphorylated Y951 is the binding and activation of the T-cell-
specific adapter (TSAd) a VEGF receptor-associated protein, which associates 
with Src and PI3K [5,6]. Blocking of PI3K pathway also results in an impaired 
nuclear translocation of VEGFR2 [11] further suggesting that Y951 is 
implicated in the nuclear translocation process of VEGFR2 in ECs. 
Taken together, the data presented here suggest that the phosphorylation of 
VEGFR2 tyrosine Y951 is essential for the nuclear translocation process of the 
receptor in ECs. Further studies are required to elucidate the biological 
relevance of this receptor in the cell nucleus. 
3.5. MATERIAL AND METHODS 
CELL CULTURE 
Primary Human Umbilical Vein Endothelial Cells (HUVEC referred as ECs) 
were kindly provided by Dr Shahin Rafii (Cornell University Medical College, 
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New York, USA). ECs, passage 4-8, were cultured in 0.02 % gelatin-coated 
dishes in growing endothelial medium (basal EBM-2 medium supplemented 
with EGM-2 singlequots, BBE and 5 % of Fetal Bovine Serum (FBS)) as 
provided by the manufacturers (Lonza, USA). HEK-293 T cells were cultured 
in DMEM (Invitrogen Corporation, USA) supplemented with 10 % FBS. 
CONSTRUCTION OF THE VEGFR2 POINT MUTANTS BY SITE DIRECTED-
MUTAGENESIS 
Tyrosine to phenylalanine VEGFR2 point mutants were generated by site-
directed mutagenesis using the overlap extension method [17]. Two separate 
amplification reactions were first performed using the pEGFP-VEGFR2 as 
template; one using the primer A: 5’ C GTC ATG GAT CCA GAT GAA CTC C 
3’ (sense) and the mutated antisense primer (listed below), the other using the 
mutated sense primer (listed below) and the primer B: 5’ TA G GT CAG GGT 
GGT CAC GAG 3’ (antisense).  
The mutated primers designed to replace tyrosine (Y) to phenylalanine (F-
bold) residues in Y951 were: 5’ GGG AAA GAC TTC GTT GGA GCA 3’ 
(sense) and 5’ TGC TCC AAC GAA GTC TTT CCC 3’ (antisense); in Y996 
were 5’ T CCT GAA GAT CTG TTT AAG GAC TTC CTG 3’ (sense) and 5’ G 
GAA GTC CTT AAA CAG ATC TTC AG 3’ (antisense); in Y1054 were 5’ GCC 
CGG GAT ATT TTT AAA GAT CCA G 3’(sense) and 5’ TGG ATC TTT AAA 
AAT ATC CCG GGC C 3’ (antisense); in Y1059 were 5’ GAT CCA GAT TTT 
GTC AGA AAA GGA G 3’ (sense) and 5’ C TCC TTT TCT GAC AAA ATC 
TGG ATC T 3’ (antisense). 
The thermal amplification conditions were 95 °C/5 min, 35 cycles (95 °C/1 min, 
61 °C/1 min, 72 °C/1 min), 72 °C/10 min. An overlapping reaction was 
performed using the mutated products from the first PCR (2–5%) and the 
sense A and antisense B primers. The thermal amplification conditions were 
95 °C/5 min, 35 cycles (95 °C/1 min, 58 °C/1 min, 72 °C/1 min), 72 °C/10 min. 
PCR products were inserted into the BamHI/ ApaI sites of pEGFP-VEGFR2. 
All constructs were confirmed by DNA sequencing. 
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GENERATION OF LENTIVIRAL VECTORS EXPRESSING VEGFR2 
The VEGFR2 WT and tyrosine to phenylalanine mutants fused to GFP were 
released from pEGFP-VEGFR2 using the SalI/ HpaI restriction sites and were 
cloned in the lentiviral plasmid FUGW (kindly given by Dr. Pedro Simas, 
Instituto de Medicina Molecular, Lisbon, Portugal) in the BamHI/ EcoRI 
restriction sites, using blunt-end cloning, generating FU-VEGFR2-GFP. All 
constructs were confirmed by DNA sequencing 
LENTIVIRAL PRODUCTION 
Lentiviral particles were obtained with the transfection of HEK-293T cells using 
a standard calcium phosphate precipitation protocol. HEK-293T cells (# 50% 
confluent) were transfected with the lentiviral vector plasmid FUGW or FU-
VEGFR2-GFP together with the HIV-1 packaging vector Delta 8.9 and the 
VSV-g envelope glycoprotein. The viral supernatants were collected 60 h post-
transfection and filtered through a 0.45 µm pore size filter. ECs were seeded 
at 7.5x104 cells (12 well plate) 24 h before transduction and then exposed to 
500 µl of virus supernatant (supplemented with polybrene to a final 
concentration of 4 µg/ ml). 72 h post-infection the GFP positive cells were 
sorted. ECs expressing FUGW were named EC GFP; ECs expressing FU-
VEGFR2(WT)-GFP were named EC VEGFR2-GFP; ECs expressing FU-
VEGFR2(Y951F/Y996F)-GFP were named EC VEGFR2(Y951F/Y996F)-GFP; 
ECs expressing FU-VEGFR2(Y1054F/Y1059F)-GFP were named EC 
VEGFR2(Y1054F/Y1059F)-GFP; ECs expressing FU-VEGFR2(Y996F)-GFP 
were named EC VEGFR2(Y996F)-GFP; ECs expressing FU-
VEGFR2(Y951F)-GFP were named EC VEGFR2(Y951F)-GFP. 
CONFOCAL MICROSCOPY 
Live cell imaging was performed at 37 ºC and 5 % CO2 on a Zeiss LSM 510 
META (Carl Zeiss, Germany) inverted laser scanning confocal microscope 
equipped with a large incubator for temperature control and a stage incubator 
for CO2 supply (PeCon, Germany). Images were acquired using a Plan-
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Apochromat 63x/1.4 oil immersion objective. GFP fluorescence was detected 
using the 488 nm line of an Ar laser (45 mW nominal output) and a BP 505-
550 nm filter. 
FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING (FRAP) 
Each FRAP analysis started with a single image scan followed by a bleach 
pulse at 100% laser power in a region of interest (ROI) that coincided with the 
cell nucleus (~ 350 mm2 area). A series of 56 single-section images were then 
acquired at 5 s intervals for 280 s, with the first image being acquired 2 ms 
after the end of the photobleaching. Image acquisition was performed with 
laser power attenuated to 1% of the bleaching intensity. 
Fluorescence intensity quantification was performed for each FRAP time 
series using ImageJ software (http://rsbweb.nih.gov.ij). The average 
fluorescence in the nucleus of bleached cells I(t) and the total cell 
fluorescence T(t) were calculated for each background-subtracted image at 
time t. FRAP curves for bleached cells were then normalized and corrected for 
loss of fluorescence due to imaging, 
I_N(t)=I(t)/I0 . T0/T(t) 
where I0 and T0 are the nuclear and total fluorescence intensities before 
bleaching started [18]. The ratio between steady-state fluorescence in nucleus 
and cytoplasm was calculated by simply dividing pre-bleach nuclear and 
cytoplasmic background-subtracted intensities. 
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4.1. ABSTRACT 
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) is the major 
mediator of the angiogenic effects of VEGF. In addition to its well-known role 
as a membrane receptor that activates multiple signaling pathways, VEGFR2 
also has a nuclear localization. However, what VEGFR2 does in the nucleus is 
still unknown. 
In the present report we show that, in endothelial cells (ECs), nuclear VEGFR2 
interacts with several nuclear proteins, including Sp1, a transcription factor 
that has been implicated in the regulation of genes needed for angiogenesis.  
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By in vivo chromatin immunoprecipitation (ChIP) assays, we found that 
VEGFR2 binds to the Sp1-responsive region of the human VEGFR2 proximal 
promoter. These results were confirmed by EMSA assays, using the same 
region of the VEGFR2 promoter. Importantly, we show that the VEGFR2 DNA 
binding is directly linked to the transcriptional activation of the VEGFR2 
promoter. By reporter assays, we found that the region between -300/-116 
relative to the transcription start site is essential to confer VEGFR2-dependent 
transcriptional activity. It was previously described that nuclear translocation of 
the VEGFR2 is dependent of its activation by VEGF. Consistently, we 
observed that the binding of VEGFR2 to DNA requires VEGF activation, being 
blocked by Bevacizumab and Sunitinib, two anti-angiogenic agents that inhibit 
VEGFR2 activation.  
Our findings demonstrate a new mechanism by which VEGFR2 activates its 
own promoter that could be involved in amplifying the angiogenic response. 
4.2. INTRODUCTION 
Angiogenesis is the formation of new blood vessels from a pre-existing 
vascular net. This process is essential during embryonic development and for 
normal homeostasis of adult tissues. In addition, angiogenesis was recognized 
to be fundamental in the progression of many pathological diseases such as 
cancer because it is an essential event in tumor growth and metastatic 
dissemination [1]. Angiogenesis is a complex dynamic process regulated by a 
balance between pro-angiogenic and anti-angiogenic factors. Vascular 
Endothelial Growth Factor (VEGF) is one of the most important pro-angiogenic 
factors. VEGF stimulates angiogenesis by binding to the VEGF receptor 
(VEGFR) 1 and VEGFR2 receptor tyrosine kinases (RTKs) on the cell surface 
of ECs, [2]. Both VEGFR1 and VEGFR2 have seven Ig-like-domains in the 
extracellular domain, a single transmembrane region and a split tyrosine 
kinase intracellular domain [2]. VEGFR2 is considered to be the major 
mediator of several physiological and pathological effects of VEGF on ECs. 
These include proliferation, survival, migration and permeability [2].  
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VEGF binds to the extracellular domain of VEGFR2 inducing receptor 
dimerization and autophosphorylation of specific intracellular tyrosine residues 
leading to the activation of different signaling pathways [2].  
Recognition of the VEGF pathway as a key regulator of angiogenesis has led 
to the development of several VEGF-targeted agents demonstrating 
therapeutic efficacy in several human cancers [3]. Therefore, several 
approaches have been developed to inhibit VEGF signaling, including 
neutralization of the ligand or receptor by antibodies, and blocking VEGF 
receptor activation and signaling with tyrosine kinase inhibitors [4]. The 
pioneers of the clinical proof-of-concept for angiogenesis inhibitors are 
Bevacizumab (Avastin®, Genentech/Roche), a ligand-trapping monoclonal 
antibody [5], and Sunitinib (Sutent®, Pfizer), which target receptor tyrosine 
kinases [6], principally VEGFR2. Their goal is to block the VEGF signaling 
mediated by the plasma membrane receptor VEGFR2.  
Besides the membrane localization of VEGFR2, it was demonstrated that it 
could also be found in the cell nucleus. In particular, phosphorylated VEGFR2 
has been observed in the nucleus of proliferative tumor and leukemia cells 
[7,8,9,10,11], suggesting that molecular mechanisms that contribute to tumor 
angiogenesis might require a specific activity of this protein in the nucleus. 
Moreover, we also demonstrated the role of the nuclear internalization of 
VEGFR2 in EC recovery following injury [12]. Taken together, these studies 
document the presence of VEGFR2 in the nucleus and suggest that nuclear 
VEGFR2 might amplify the angiogenic response. However, the precise activity 
of VEGFR2 in the nucleus is unknown.  
Here, we demonstrate a previously unrecognized function for nuclear VEGFR2 
as a putative transcription factor that is involved in the regulation of its own 
transcription. We show that VEGFR2 binds to and activates its own promoter 
in vivo in VEGF-activated ECs. Moreover, we observed that this mechanism is 
blocked by treating ECs with Bevacizumab or Sunitinib.  
VEGFR2 REGULATES ITS OWN TRANSCRIPTION 
 
 94 
4.3. RESULTS 
VEGFR2 NUCLEAR INTERNALIZATION IS A DYNAMIC PROCESS THAT IS 
CORRELATED WITH TRANSCRIPTIONAL ACTIVITY IN ECS  
In order to investigate the functional relevance of nuclear VEGFR2 we 
established an EC model of VEGFR2 overexpression (EC VEGFR2 IRES 
GFP) using a lentiviral infection approach. Positively transduced cells were 
sorted using GFP expression and VEGFR2 overexpression was confirmed by 
both immunofluorescence and confocal microscopy (Figure 1A) and western-
blot analysis (Figure 2A, first panel). By confocal analysis we found that 
VEGFR2 expression was increased both in the cytoplasm and nucleus of      
EC VEGFR2 IRES GFP, when compared to untransduced EC or EC 
transduced with a control vector (EC IRES GFP), (Figure 1A). Our data 
suggest that ECs overexpressing VEGFR2 results in high levels of this protein 
that are not degraded and also accumulate in the nucleus.  
We decided to further investigate the nuclear internalization of VEGFR2 by 
performing photobleaching studies on living ECs to measure the nuclear 
turnover of GFP tagged VEGFR2. First, we photobleached VEGFR2-GFP in 
the whole cell nucleus and then quantified the nuclear fluorescence recovery 
by time-lapse imaging. According to our results, a full recovery of the 
fluorescence signal was observed within 100 s (Figure 1B, upper panel and 
1C), suggesting a rapid turnover of VEGFR2-GFP between the cytoplasm and 
the nucleus.  
Interestingly, we also found that a single point mutation at tyrosine residue 
Y951 of the VEGFR2 results in a slower turnover rate compared to ECs 
expressing the wild-type protein, with fluorescence intensity not recovering to 
its pre-photobleaching baseline within the duration of FRAP experiment.  
ECs expressing mutations in other tyrosine residues (such as Y1059, Y1054 
and Y996) were evaluated and presented similar recovery kinetics following 
bleaching when compared to VEGFR2-GFP cells (Figure 1C). 
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Figure 1. VEGFR2 nuclear translocation is a rapid process that is affected by the VEGFR2 
tyrosine Y951.  
(A) EC, EC IRES GFP and EC VEGFR2 IRES GFP were cultured in growing media and VEGFR2 
overexpression was analysed by immunofluorescence. Cells were stained with a rabbit anti-human 
VEGFR2 antibody (Alexa 594). Results shown are representative z-projections of at least three 
independent experiments. Scale bar: 20 µm. Right panel shows mean fluorescence intensity of 
VEGFR2 in the cell nucleus. *P<0.0001. (B and C) FRAP analysis was performed in EC VEGFR2-GFP 
and mutants EC VEGFR2(Y1054F/Y1059F)-GFP, EC VEGFR2(Y996F)-GFP and                                
EC VEGFR2(Y951F)-GFP. Fluorescence signal of the entire nucleus was photobleached with a single 
488-nm high intensity laser pulse and subsequent fluorescence recovery was recorded for 280 s.      
(B) Selected images of VEGFR2-GFP protein in EC VEGFR2-GFP (upper panel) and                              
EC VEGFR2(Y951F)-GFP (lower panel) before bleaching (steady-state) and at the indicated intervals 
post-bleaching (from 5 to 100 s). White circles indicate the bleached region. (C) Fluorescence intensity 
in the bleached region was measured every 5 s for 280 s and normalized for the initial intensity. Data 
show results obtained in three independent experiments, with at least ten different cells analysed in 
each case. Error bars represent standard deviation (SD). 
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Taken together, our results suggest that the translocation of VEGFR2 from the 
cytoplasm to the nucleus is a rapid and dynamic process in which the tyrosine 
residue Y951 plays an important role. 
Because VEGFR2 signaling promotes cell proliferation and survival, we tested 
if increased levels of VEGFR2 modified the levels of nuclear proteins involved 
in these processes. We observed increased levels of Cyclin A, p65 (NF%B) 
and Sp1 in the nucleus of EC VEGFR2 IRES GFP, compared to control        
EC IRES GFP (Figure 2A). The expression of YY1 was not significantly altered 
in the same cells (Figure 2A). Since some of these nuclear proteins are 
transcription factors (TFs), we evaluated whether their nuclear expression 
levels were mirrored by a change in their DNA binding activities using EMSA 
assays. We found a p65 (NF%B) increased DNA binding activity in the 
VEGFR2 overexpressing cells, compared to control EC IRES GFP (Figure 2B, 
left panel), which is consistent with the increased protein levels in the nucleus 
(Figure 2A). Interestingly, the DNA binding activity of YY1 was also increased 
in ECs overexpressing VEGFR2 (Figure 2B, right panel). These results 
indicate that binding activities of several TFs are increased in ECs expressing 
VEGFR2, suggesting an enhanced transcriptional activity in these cells.  
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Figure 2. VEGFR2 nuclear internalization levels correlate with transcriptional activity of ECs.  
(A) Cytoplasmic (C) and nuclear extracts (N) from EC IRES GFP and EC VEGFR2 IRES GFP were 
analysed by Western blot with antibodies against VEGFR2, Cyclin A, Sp1, p65, YY1. P-I%B and     
Lamin B were used as cytoplasmic and nuclear controls, respectively. (B) Nuclear extracts from        
EC IRES GFP (lanes 2,7) and EC VEGFR2 IRES GFP (lanes 3,8) were incubated with NF%B (left 
panel, lanes 2 and 3) or YY1 (right panel, lanes 7 and 8) radiolabeled probes. Four NF%B (C1-C4) or 
five YY1 complexes (C1-C5) are indicated with black arrows. Specific anti-p65 (lane 4) or anti-YY1 
(lane 9) were introduced in the binding reaction to analyse the appearance of a supershift complex (as 
indicated in both panels) in EC VEGFR2 IRES GFP cells. Using the same cells, a competitive assay 
using 100x excess of cold probe of NF%B (lane 5) or YY1 (lane10) was performed. Control lanes 1 and 
6 contain only the radiolabeled probes. (C) ECs were cultured in growing media, treated or not with 
6.12 Ab for 1 h and incubated with 5-FU for 15 min. (D) ECs were cultured in growing media and 
transfected with scrambled siRNA or VEGFR2 siRNA. ECs were incubated with 5-FU for 15 min, 24 h 
post-transfection. (C and D) Cells were fixed, sequentially labeled, on the same slide with a rabbit anti-
human VEGFR2 (Alexa 594) and a mouse anti-human BrdU antibody (Alexa 488) and analysed by 
confocal microscopy. Results shown are representative z-projections of three independent 
experiments. Scale bar: 20 µm. 
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For that reason, we decided to test if the levels of transcription in ECs were 
also altered when the nuclear accumulation of VEGFR2 was experimentally 
reduced. For this, we took advantage of our previous observation that a 
neutralizing antibody against VEGFR1 (6.12 Ab) decreases VEGFR2 levels in 
the nucleus [12]. Using a 5-fluorouracil (5-FU) incorporation assay, we 
observed that the levels of transcription were decreased after 6.12 Ab 
treatment, compared to control cells (Figure 2C). Similar results were obtained 
when the levels of VEGFR2 were reduced by using the siRNA technology 
(Figure 2D). As shown in Figure S1A, a pool of VEGFR2 siRNA oligos used in 
our experiments effectively abrogated the VEGFR2 expression as assessed 
by qRT-PCR (by 70% compared with the scrambled siRNA oligos). 
Taken together, these results suggest that the levels of EC transcription could 
be correlated with the nuclear accumulation of VEGFR2. 
NUCLEAR VEGFR2 INTERACTS WITH THE TRANSCRIPTION FACTOR SP1 IN THE 
NUCLEUS OF ECS 
The above results suggest that the nuclear levels of VEGFR2 could modulate 
cell transcription and we decided to investigate the specific role of VEGFR2 in 
this process. We asked if VEGFR2 interacts with nuclear proteins and if it 
modulates cell transcription. To address this question, VEGFR2 was 
immunoprecipitated from EC nuclear extracts and the proteins that directly or 
indirectly interacted with VEGFR2 were identified by Mass Spectrometry (MS) 
analysis (Figure 3A and 3B). Approximately 310 proteins were identified with 
high confidence with the Mascot algorithm. Proteins with a Mascot score 
greater than 200 were listed in Table S1. Analysis of these possible partners 
with Ingenuity Pathway Analysis (IPA) identified 95 proteins in 22 enriched 
categories for biological functions as represented in Figure 3B.  
CHAPTER IV
 
99 
 
 
Figure 3. Nuclear VEGFR2 interacts with the transcription factor Sp1 in the nucleus of ECs.  
(A) Immunoprecipitation (IP) of 1 mg EC nuclear extract with anti-human VEGFR2 was performed and 
resolved in 8% SDS-PAGE, following silver staining (lane 2). VEGFR2 antibody plus beads (without N) 
were used as negative control for immunoprecipitation (lane 1). The protein marker is shown as 
molecular weight (MW) in thousands. (B) Representation of the mass spectrometry analysis of the 
nuclear VEGFR2 IP, showing the categories for the different biological functions of the identified 
proteins (p < 0.05). (C) Immunoprecipitation (IP) of EC nuclear extracts (N) was conducted with the 
VEGFR2 (lane 2), Sp1 (lane 4) and rabbit IgG (rIgG-lane 5) antibodies followed by VEGFR2 (upper 
panel) or Sp1 (lower panel) immunoblotting. VEGFR2 (lane 1) or Sp1 (lane 3) antibodies plus beads 
(without N) were used as negative controls for immunoprecipitation. Non-immunoprecipitated nuclear 
cell extract (lane 6) was also included in the experiment. (D) Pull-down assay: Sp1 protein fused to a 
HA tag was incubated with GST alone (lanes 1 and 2) or VEGFR2 (789-1356)-GST (lanes 3 and 4). 
GST-unbound (UB) (lanes 1 and 3) and bound (B) fractions (lanes 2 and 4) were loaded and analyzed 
with GST (upper panel) and Sp1 (lower panel) antibodies.   
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Interestingly, proteins involved in gene expression are among the most 
abundant, suggesting that nuclear VEGFR2 could interact with proteins 
involved in gene transcription.  
In order to confirm the data obtained by MS, we performed western-blot on 
nuclear VEGFR2 immunoprecipitates. We confirmed an interaction between 
VEGFR2 and Sp1 (Figure 3C). Interestingly, Sp1 is a transcription factor that 
regulates multiple genes important to angiogenesis. The antibody against Sp1 
does not cross-react with other members of the Sp family, indicating a specific 
interaction between VEGFR2 and Sp1. Furthermore, we performed pull-down 
assays using purified proteins and our results suggest an interaction between 
Sp1 and the region containing amino acids 789 to 1356 of VEGFR2 (Figure 
3D). 
NUCLEAR VEGFR2 BINDS TO AND ACTIVATES THE VEGFR2 PROXIMAL 
PROMOTER IN ECS 
Since it was previously shown that Sp1 is involved in the transcriptional 
regulation of VEGFR2 gene [13,14] and because our results suggest a nuclear 
interaction between Sp1 and VEGFR2 (Figure 3C and 3D), we hypothesized 
that VEGFR2 could be involved in the regulation of its own transcription. In 
order to answer to this question, we decided to investigate if VEGFR2 could 
bind to its own promoter. Quantitative ChIP assays were performed on ECs, 
cultured in growing media. We chose a region of the human VEGFR2 proximal 
promoter that comprises five Sp1 binding sites between -300/+1 relative to the 
transcription start site (Figure 4A). We observed that Sp1 binds to the 
VEGFR2 proximal promoter (4.2 fold ± 0.14 increase relative to the control 
IgG), (Figure 4B), which was consistent with previous reports [13,15]. 
Interestingly, we observed a 13.8 fold ± 0.55 increase in binding of VEGFR2 
relative to the negative control IgG (Figure 4B). As expected, when ECs were 
transfected with Sp1 siRNA in order to reduce its expression, the binding of 
Sp1 to the VEGFR2 promoter was significantly decreased (Figure 4C). 
Moreover, the binding of VEGFR2 to its own promoter was abrogated in ECs 
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transfected with VEGFR2 siRNA (Figure 4C). Note that in both transfections, 
the expression of Sp1 and VEGFR2 were downregulated approximately 70% 
compared with that of scrambled siRNA-transfected ECs (Figure S1). 
Curiously, we also found that the binding of Sp1 to VEGFR2 promoter was 
significantly increased when the expression of VEGFR2 was downregulated 
by siRNA. In contrast, the binding of VEGFR2 to its own promoter was 
reduced in ECs transfected with Sp1 siRNA (Figure 4C).  
In order to confirm that VEGFR2 binds to its own promoter, we performed 
EMSA assays using as a probe the same region of the VEGFR2 proximal 
promoter analyzed by ChIP. We identified four complexes (C1-C4) with distinct 
electrophoretic mobilities (Figure 4D, lane 2), which did not form when an 
excess of cold probe was introduced in the reaction (Figure 4D, lane 4), 
establishing their specificity.  
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Figure 4. Nuclear VEGFR2 binds to the VEGFR2 proximal promoter in ECs.  
(A) Sequence of the human VEGFR2 proximal promoter (retrieved from Ensemble database accession 
number: ENSG00000128052) and underlined of the putative Sp1 binding sites. The transcription start 
site is indicated in gray. (B) ChIP assays of the VEGFR2 proximal promoter were performed using ECs 
cultured in growing media. Antibodies against VEGFR2 and Sp1 were used. Normal rabbit/mouse IgG 
were used as control. Also, an antibody for RNA Pol II was used to test the promoter activity. All values 
are relative to control IgG background and normalized to an intergenic region. Data are mean ± s.e.m. 
of triplicates and represents three independent experiments. (C) ChIP assays of the VEGFR2 proximal 
promoter were performed in ECs 24 h post-transfection of scrambled siRNA or VEGFR2 siRNA or Sp1 
siRNA. Antibodies against VEGFR2 and Sp1 were used. Normal rabbit IgG was used as control. 
Values are relative to control IgG background and normalized to an intergenic region. Data are mean ± 
s.e.m. of triplicates and represents three independent experiments. (D) EMSA analysis of the VEGFR2 
promoter with EC nuclear extracts (lane 2) or VEGFR2 immunodepleted (ID VEGFR2) extract (lane 3) 
was conducted. Four complexes (C1-C4) are indicated with black arrows. A competitive assay using 
100x excess of cold probe of VEGFR2 promoter was conducted (lane 4) using EC nuclear extract. 
Control lane 1 contains only the radiolabeled probe. 
To evaluate the presence of VEGFR2 in the shifted complexes, we first tried a 
supershift assay using an antibody against VEGFR2, which failed to produce 
any change in the mobility of the shifted complexes (data not shown). As the 
VEGFR2 antibodies were active in immunoprecipitation experiments, we used 
an immunodepletion approach to evaluate the presence of VEGFR2 in the 
shifted complexes. Using these VEGFR2-immunodepleted nuclear extracts in 
the EMSA assays we observed an absence of the C2 complex and a strong 
reduction in the intensity of the C1 complex while the C3 and C4 complexes 
were not significantly altered (Figure 4D, lane 3). An IgG-depleted control 
extract did not affect the intensity of these complexes (Figure S2B). 
Simultaneously, the VEGFR2 depletion in the protein extracts was confirmed 
by western-blot (Figure S2A). These results are consistent with the presence 
of VEGFR2 in the C1 and C2 complexes. A similar experiment performed 
using Sp1-depleted extract showed a decrease in the intensity of C1 and C2 
complexes (Figure S2B), suggesting that Sp1 and VEGFR2 are present in the 
same DNA/protein complexes. 
Finally, we investigated the ability of the nuclear VEGFR2 to transcriptionally 
activate its own promoter using luciferase reporter assays.  
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For these experiments we used the 3T3 VEGFR2-GFP cells, which 
constitutively express VEGFR2, and compared to control 3T3 GFP cells that 
do not express VEGFR2 [12]. Transfection of a pGL3 control vector alone did 
not produce significant differences in luciferase activities in both cell lines 
(Figure 5A).  
 
Figure 5. Nuclear VEGFR2 activates the human VEGFR2 proximal promoter. 
(A) NIH 3T3 GFP and NIH 3T3 VEGFR2-GFP were transfected with pGL3 control or pGL3 VEGFR2    
(-300/+1) or pGL3 VEGFR2 (-116/+1). The "-gal plasmid was co-transfected as a control. Promoter 
activities were measured with luciferase activity normalized to "-gal. The results are expressed as the 
relative luciferase activities. Data are mean ± s.e.m. of relative luciferase activities from four 
independent experiments, each performed in triplicate. *p = 0.007; **p = 0.001). (B) NIH 3T3 VEGFR2-
GFP were transfected with scrambled siRNA, VEGFR2 siRNA or Sp1 siRNA. At 48 h post-transfection 
the relative luciferase activity of pGL3 control or pGL3 VEGFR2 (-300/+1) was measured. Data are 
mean ± s.e.m. of relative luciferase activities from three independent experiments, each performed in 
triplicate, (*p =0.003). 
However, when we transfected a construct including the VEGFR2 proximal 
promoter spanning -300/+1, we observed a significantly higher luciferase 
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activity in the VEGFR2-GFP cells (4.8 fold ± 0.88, p=0.007) compared to 
control cells (2.4 fold ± 0.22), (Figure 5A). Specifically, we confirmed a 
reduction in luciferase activity in VEGFR2-GFP cells co-transfected with 
VEGFR2 siRNA when compared to scrambled siRNA-co-transfected cells 
(Figure 5B). Moreover, no increased luciferase activity over basal levels (1.74 
fold ± 0.8) was observed in the 3T3 VEGFR2-GFP cells, when transfected with 
a reporter construct containing a shorter fragment (-116/+1) of the VEGFR2 
promoter (Figure 5A). These results suggest that VEGFR2 is indeed able to 
activate transcription from its own promoter and that this activation requires 
the region between -300/-116 relative to the transcription start site.  
Consistent with our previous findings where we found a decrease of the 
binding of VEGFR2 to its own promoter when the expression of Sp1 was 
reduced by siRNA (Figure 4C), we also observed a significant decrease of the 
luciferase activity in VEGFR2-GFP cells co-transfected with Sp1 siRNA 
(Figure 5B). 
Taken together, these data strongly suggest a previously unrecognized 
function of nuclear VEGFR2 as a possible transcription factor involved in the 
regulation of its own transcription. 
VEGFR2 BINDING TO ITS OWN PROMOTER IS DEPENDENT OF VEGFR2 ACTIVATION 
To further analyze the possible functional relevance of the VEGFR2 binding to 
its own promoter, we took advantage of our finding that VEGFR2 nuclear 
translocation requires activation by VEGF [12]. We did not observe DNA 
binding of VEGFR2 (0.2 fold ± 0.03) when ECs were cultured under basal 
medium (without supplements or serum), which is consistent with the absence 
of nuclear VEGFR2 in these culture conditions [12]. Also, the Sp1 binding was 
negligible under these conditions (2.3 fold ± 0.13), (Figure 6A).  
However, after 30 min of VEGF stimulation, we observed a strong increase in 
binding of VEGFR2 (159.6 fold ± 5.21) to its own promoter (Figure 6A). In the 
same cells, we failed to observe an increment of Sp1 binding (1.03 fold ± 0.17, 
relative to control IgG), (Figure 6A).  
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Figure 6. VEGFR2 binding to its own promoter is dependent of VEGFR2 activation. 
ChIP assays of the VEGFR2 proximal promoter were performed using (A) ECs cultured in basal 
medium for 48 h, and were left unstimulated or stimulated with VEGF (20 ng/ml) for 30 min. Antibodies 
against VEGFR2 and Sp1 were used. Normal rabbit/mouse IgG were used as control. Also, an 
antibody for RNA Pol II was used to test the promoter activity. Values are relative to control IgG 
background and normalized to an intergenic region. Data are mean ± s.e.m. of triplicates and 
represents three independent experiments. (B) ECs cultured in growing media were left untreated or 
treated with 0.5 mg/ml Bevacizumab (left panel) or 0.1 µM Sunitinib (right panel) for 16 h. In the 
Sunitinib experiments, DMSO was used as vehicle. ChIP values are relative to control IgG and 
normalized to an intergenic region. Data are mean ± s.e.m. of triplicates and represents three 
independent experiments. 
These results demonstrate that VEGFR2 activation by VEGF is crucial for 
VEGFR2 binding to its own promoter in vivo, suggesting that VEGFR2, as a 
nuclear protein, could be involved in amplifying the angiogenic response. To 
further explore this idea, we treated ECs with two anti-angiogenic agents, 
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which block the VEGFR2 activation, in order to evaluate their effect on 
VEGFR2 binding to its own promoter. Our results showed that both 
Bevacizumab, a monoclonal antibody against VEGF and Sunitinib, a VEGFR2 
tyrosine kinase inhibitor, led to a strong reduction of the binding of VEGFR2 to 
its own promoter, as estimated by quantitative ChIP (Figure 6B).  
These results were relatively specific to VEGFR2 inhibitors as no effect on 
VEGFR2 binding was detected when ECs were treated with Iressa, an 
epidermal growth factor receptor-tyrosine kinase inhibitor (Figure S3). 
4.4. DISCUSSION 
The classical view of signaling through VEGFR2 considers that the membrane 
receptor is phosphorylated upon ligand binding, activating intracellular 
signaling cascades that regulate a wide range of biological outcomes, 
including cellular survival, proliferation, migration and differentiation [2]. Until 
recently, internalization of VEGFR2 was thought to be the pathway for 
downregulation of the signaling through receptor degradation. Consistent with 
this, it was found that VEGFR2 is ubiquitylated by c-Cbl [16] and that activated 
PKC marks the receptor for internalization and degradation [17]. However, 
increasing evidence indicates that internalized VEGFR2 may also have 
signaling activity. For instance, it has been shown that phosphorylated 
VEGFR2 can be internalized in a VE-cadherin-dependent manner to 
endosomal compartments, retaining activation of signaling pathways and 
sustaining cell proliferation and migration, rather than receptor degradation 
[18]. Recently, it was shown that ephrinB2 activation controls VEGFR2 
internalization, which is required for activation and downstream signaling of 
the receptor during vascular sprouting in physiological and pathological 
conditions [19,20]. We also demonstrated that the nuclear internalization of 
VEGFR2 is required for endothelial recovery following injury [12]. Finally, we 
and others found constitutive nuclear localization of VEGFR2 in proliferative 
tumor cells, suggesting that this protein may be involved in nuclear molecular 
mechanisms that contribute to tumor progression [7,8,9,10,11].  
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Taken together, these different studies suggest that the intracellular trafficking 
of VEGFR2 is linked to its signaling activity that contributes to the amplification 
of the angiogenic response.  
In the present report we have shown in living ECs that VEGFR2 rapidly 
translocates to the nucleus and the VEGFR2 tyrosine residue Y951 plays an 
important role in this dynamic process. The role that VEGFR2 might play in the 
nucleus has remained undisclosed. Here, we show for the first time to our 
knowledge that nuclear VEGFR2 has transcriptional activity. In particular, we 
show that VEGFR2 binds to its own promoter in VEGFR2-activated ECs in 
vivo and that VEGFR2 can activate transcription from this promoter in reporter 
assays. These findings suggest that VEGFR2 might participate in the positive 
feedback regulation of its own expression. This is consistent with previous 
reports showing that VEGF binding to membrane VEGFR2 results in 
increased levels of VEGFR2 gene transcription and protein expression [21]. 
Similarly, it was observed that mechanoactivation produces translocation of 
VEGFR2 to the nucleus [22], which is accompanied by an upregulation of the 
VEGFR2 gene transcription [23].  
Our results now indicate that this increase in VEGFR2 expression depends, at 
least in part on VEGFR2 transcriptional activity. Our EMSA data revealed the 
existence of different VEGFR2 containing complexes (C1 and C2 complexes) 
with different mobilities when bound to the promoter, suggesting that VEGFR2 
interacts with additional molecules when bound to DNA. Our MS profiling data 
seems to support this idea. In particular, Sp1 stands out as one of the 
VEGFR2-interacting proteins in the nucleus of ECs. This is consistent with 
previous data showing that Sp1 is implicated in the transcriptional regulation of 
genes important to angiogenesis, including, VEGF and VEGFR2 [13,14,24]. 
These two molecules interact, as shown by co-immunoprecipitation 
experiments. Pull-down assay experiments using purified proteins further 
confirmed that the interaction between VEGFR2 and Sp1 is direct. Our EMSA 
data using Sp1 or VEGFR2 depleted extracts also indicate that Sp1 and 
VEGFR2 are present in the same protein-DNA complexes. Interestingly, the    
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-300/+1 bp region of the VEGFR2 promoter, identified as one of the key 
elements for the regulation of VEGFR2 expression [14,15,25,26], contains five 
Sp1 binding sites and is able to bind both Sp1 and VEGFR2. Our reporter 
assays show that the region between -300/-116 relative to transcription start 
site is essential to confer the VEGFR2 promoter VEGFR2-dependent 
transcriptional activity. Moreover, our results indicate that VEGFR2 is essential 
for the activity of its own promoter since cells that do not express VEGFR2 
have significantly lower levels of the VEGFR2 promoter activity compared to 
VEGFR2-expressing cells. Accordingly, the levels of the VEGFR2 promoter 
activity observed in VEGFR2-expressing cells are significantly decreased if the 
expression of VEGFR2 is reduced by siRNA. However, at the moment we do 
not know if VEGFR2 binds to a consensus DNA sequence and the nature of 
this sequence. Clearly, identification of other transcriptional targets of 
VEGFR2 will help to address this issue. Also, understanding the mechanism of 
VEGFR2 transcriptional activity will require the complete identification of the 
molecules interacting with VEGFR2 at the promoters/enhancers. In ECs, 
binding of VEGFR2 to DNA requires VEGF-activation, since this binding 
cannot be detected in ECs cultured in the absence of this growth factor. 
Moreover, ECs treated with anti-angiogenic agents that block VEGFR2 
activation present negligible levels of VEGFR2 DNA binding activity. This is 
consistent with the finding that the nuclear translocation of the receptor is 
dependent of VEGF activation [12], and further supports the idea that nuclear 
translocation/transcriptional activity of VEGFR2 is an integral part of the 
signaling mediated by this receptor.  
While in ECs VEGFR2 nuclear translocation and consequently its DNA binding 
depends on VEGFR2 activation by VEGF, it has been reported that some 
tumor cells present constitutive nuclear localization of VEGFR2. If these tumor 
cells also present constitutive VEGFR2 transcriptional activity, this could result 
in resistance to anti-VEGF therapies. Several anti-VEGF strategies have been 
developed, including neutralizing antibodies to VEGF such as Bevacizumab 
[5] or tyrosine kinase inhibitors such as Sunitinib [6]. Their goal is to block the 
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VEGF signaling mediated by the membrane receptor VEGFR2. However, 
these anti-angiogenic inhibitors are not effective in all tumors, and the benefit 
even for responding patients is usually modest, indicating that mechanisms of 
intrinsic and evasive resistance to anti-VEGF therapy do exist [27]. Therefore, 
the analysis of VEGFR2 transcriptional activity in those tumors and the 
identification of the target genes will surely help to better understand its role in 
tumor angiogenesis and to devise novel therapeutic approaches.  
In conclusion, our findings provide novel insights into the role of VEGFR2 as a 
nuclear protein. Here, we demonstrate that in VEGF-activated ECs, nuclear 
VEGFR2 may act as a transcription factor by binding to and activating its own 
promoter. By this mechanism nuclear VEGFR2 could be involved in amplifying 
the angiogenic response.  
4.5. MATERIALS AND METHODS 
REAGENTS 
VEGF (20 ng/ml) was purchased from Sigma-Aldrich, USA. Bevacizumab 
(Avastin®, Genentech/ Roche, USA), (0.5 mg/ml) was provided by the 
Oncology Service of Santa Maria Hospital. Sunitinib (0.1 µM) was provided by 
Pfizer International, USA. Iressa (0.1 µM) was purchased from Tocris 
Bioscience, UK. 5-fluorouracil (5-FU, 2 mM) was purchased from Sigma-
Aldrich, USA. 
CELL CULTURE 
Primary Human Umbilical Vein Endothelial Cells (HUVEC referred as ECs) 
were kindly provided by Dr Shahin Rafii (Cornell University Medical College, 
New York, USA). ECs, passage 4-8, were cultured in 0.02 % gelatin-coated 
dishes in growing endothelial medium (basal EBM-2 medium supplemented 
with EGM-2 singlequots, BBE and 5 % of Fetal Bovine Serum (FBS)) as 
provided by the manufacturers (Lonza, USA). In basal media experiments, 
upon reaching confluence ECs were cultured in basal EBM-2 medium for 48 h. 
HEK-293 T cells were cultured in DMEM (Invitrogen Corporation, USA) 
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supplemented with 10 % FBS. NIH 3T3 GFP and NIH 3T3 VEGFR2-GFP cells 
were described and characterized in [12] and were cultured in DMEM 
supplemented with 10 % FBS and 800 µg/ml Neomycin-G418 (Invitrogen 
Corporation, USA).  
GENERATION OF LENTIVIRAL VECTORS EXPRESSING VEGFR2 
The lentiviral vector FU IRES GFP was generated by replacing the GFP of 
FUGW with the IRES GFP from pIRES GFP (Stratagene Inc., USA). FU-
VEGFR2 IRES GFP was generated by releasing full length VEGFR2 from 
pSP73-VEGFR2 using KpnI/ XhoI restriction sites and cloned in FU-IRES GFP 
using the BamHI restriction site by blunt-end cloning. All constructs were 
confirmed by DNA sequencing. 
LENTIVIRAL PRODUCTION 
Lentiviral particles were obtained with the transfection of HEK-293T cells using 
a standard calcium phosphate precipitation protocol. HEK-293T cells (# 50 % 
confluent) were transfected with the lentiviral vector plasmids FU-IRES GFP or 
FU-VEGFR2 IRES GFP together with the HIV-1 packaging vector Delta 8.9 
and the VSV-g envelope glycoprotein. The viral supernatants were collected 
60 h post-transfection and filtered through a 0.45 µm pore size filter. ECs were 
seeded at 7.5x104 cells (12 well plate) 24 h before transduction and then 
exposed to 500 µl of virus supernatant (supplemented with polybrene to a final 
concentration of 4 µg/ml). 72 h post-infection the GFP positive cells were 
sorted by FACS Aria (Becton, Dickinson and Company, USA). ECs expressing 
FU-IRES GFP were named EC IRES GFP; ECs expressing FU-VEGFR2 
IRES GFP were named EC VEGFR2 IRES GFP. 
IMMUNOFLUORESCENCE AND CONFOCAL MICROSCOPY 
ECs were cultured on gelatin-coated glass coverslips. The cells were fixed in 
1% (v/v) formaldehyde/ PBS, for 10 min, at 4 °C and washed in PBS. After 
permeabilization with 0.1% (v/v) Triton X-100 plus 5% (v/v) normal serum, 
cells were incubated in different conditions with the following antibodies: 
VEGFR2 REGULATES ITS OWN TRANSCRIPTION 
 
 112 
VEGFR2 (Santa Cruz Biotechnology, USA) at 4 ºC, overnight, followed by 
incubation with Alexa Fluor 594 (Molecular Probes, Invitrogen Corporation, 
USA) for an additional hour, at room temperature or BrdU (Sigma-Aldrich, 
USA), for 30 min, at room temperature, followed by incubation with Alexa Fluor 
488 (Molecular Probes, Invitrogen Corporation, USA) for additional 30 min, at 
room temperature. The samples were mounted in Vectashield (Vector 
Laboratories, USA) and analyzed by confocal microscopy. Sets of optical 
sections of 5 µm intervals along the Z-axis (from bottom to top of cells) were 
acquired on a Zeiss LSM 510 META (Carl Zeiss, Germany) inverted laser 
scanning confocal microscope using a PlanApochromat 63x/1.4 oil immersion 
objective. Alexa Fluor 488 and GFP fluorescence were detected using the 488 
nm line of an Ar laser (45 mW nominal output) and a BP 505-550 nm filter. 
Alexa Fluor 594 fluorescence was detected using a 594 nm HeNe laser (2 mW 
nominal output) and a LP 615 nm filter. Potential bleed-through from the 
different fluorophores was avoided by performing sequential multi-track/frame 
imaging sequences. Z-projections were obtained using ImageJ 
(http://rsbweb.nih.gov/ij/). 
5-FU INCORPORATION 
ECs were cultured in growing media on gelatin-coated glass coverslips, 
treated with 6.12 Ab (1 µg/ml) and scrambled or VEGFR2 siRNA following 
incubation with 5-FU (2 mM) for 15 min. The cells were fixed, permeabilized, 
and sequentially labeled for BrdU and VEGFR2 according to the 
immunofluorescence protocol described above.  
RNA INTERFERENCE 
SMART pool siRNA targeting human VEGFR2 or human Sp1 and non-
targeting pool siRNA (scrambled siRNA) were purchased from Dharmacon 
(UK). Knockdown of VEGFR2 or Sp1 was performed according to the 
manufacturer's recommendation. Briefly, ECs were transfected with VEGFR2, 
Sp1 or scrambled siRNA (50 nM) using the Dharmafect 4 reagent 
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(Dharmacon, UK). After 24 h, cells were used in qRT-PCR, ChIP, 5FU-
incorporation or luciferase assays. 
CELL FRACTIONATION AND WESTERN BLOT ANALYSIS 
Nuclear and cytoplasmic protein extracts were prepared as described [12]. 
Equal amounts of protein extracts were separated by SDS–PAGE, transferred 
to nitrocellulose and probed with antibodies against VEGFR2, P-I%B (both 
from Cell Signaling Technology Inc., USA), Cyclin A, Sp1, p65, YY1, Lamin B 
(all from Santa Cruz Biotecnology, USA) 
IMMUNOPRECIPITATION 
Nuclear extracts were pre-cleared with 25 µl of protein G-Sepharose beads 
(Sigma-Aldrich, USA). Nuclear protein supernatants were incubated with 
antibodies against VEGFR2 (Cell Signaling Technology Inc., USA) or Sp1 
(Santa Cruz Biotecnology, USA) and rabbit control IgG (Santa Cruz 
Biotecnology, USA) overnight, at 4 °C, and incubated with protein                  
G-Sepharose beads for an additional hour, at 4 °C. Beads were washed once 
in a lysis buffer containing 500 mM NaCl and twice in a lysis buffer containing 
150 mM NaCl. Beads were resuspended in SDS loading buffer and boiled for 
5 min. Samples were separated by SDS-PAGE followed by Western blot 
analysis or silver staining for mass spectrometry analysis.  
PULL-DOWN ASSAYS 
The GST fusion protein containing amino acids between 789-1356 of human 
VEGFR2 (VEGFR2 (789-1356)-GST) was purchased from Sigma-Aldrich, 
USA. The Sp1 protein fused to a HA-tag (Sp1-HA) was obtained from Enzo 
Life Sciences, USA. For pull-down assays, 3 µg of Sp1-HA were incubated 
with glutathione-sepharose 4B beads (GE Healthcare, USA) for 1 h, at 4 °C, in 
binding buffer containing 50 mM Tris-HCl pH7.5, 150 mM NaCl, 10% Glicerol, 
1% NP-40, 1 mM orthovanadate and complete protease inhibitors. The beads 
were spin down and the pre-cleared supernatant was incubated with 3 µg of 
purified GST or VEGFR2 (789-1356)-GST proteins overnight, at 4 °C. Peptide 
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complexes were recovered with 20 µl of glutathione-sepharose beads for 1 h, 
at 4 °C. The supernatants were kept as the unbound fractions (UB) and the 
beads were washed eight times in the binding buffer. Protein were eluted from 
the beads in reducing laemmli’s buffer, resolved by SDS-PAGE, transferred to 
nitrocellulose and analyzed by Western blot with the indicated antibodies. 
MASS SPECTROMETRY 
1D SDS-PAGE gel lanes were cut into 2 mm slices using an automatic gel 
slicer and subjected to in-gel reduction with dithiothreitol, alkylation with 
iodoacetamide and digestion with trypsin (Promega Corporation, USA, 
sequencing grade), essentially as described [28]. Nanoflow LC-MS/MS was 
performed on an 1100 series capillary LC system (Agilent Technologies, USA) 
coupled to an LTQ linear ion trap mass spectrometer (Thermo Fisher Scientific 
Inc) operating in positive mode and equipped with a nanospray source. 
Peptide mixtures were trapped on a ReproSil C18 reversed phase column (Dr 
Maisch GmbH; column dimensions 1.5 cm $ 100 µm, packed in-house) at a 
flow rate of 8 µl/min. Peptide separation was performed on ReproSil C18 
reversed phase column (Dr Maisch GmbH; column dimensions 15 cm $ 50 
µm, packed in-house) using a linear gradient from 0 to 80 % B (A = 0.1 % 
formic acid; B = 80 % (v/v) acetonitrile, 0.1 % formic acid) in 70 min and at a 
constant flow rate of 200 nl/min using a splitter. The column eluent was 
directly sprayed into the ESI source of the mass spectrometer. Mass spectra 
were acquired in continuum mode; fragmentation of the peptides was 
performed in data-dependent mode. Peak lists were automatically created 
from raw data files using the Mascot Distiller software (version 2.1; 
MatrixScience). The Mascot search algorithm (version 2.2, MatrixScience) was 
used for searching against the SwissProt database (release 
SwissProt_54.8.fasta; taxonomy: mammalian). The peptide tolerance was 
typically set to 2 Da and the fragment ion tolerance was set to 0.8 Da. A 
maximum number of 2 missed cleavages by trypsin were allowed and 
carbamidomethylated cysteine and oxidized methionine were set as fixed and 
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variable modifications, respectively. The Mascot score cut-off value for a 
positive protein hit was set to 60. Individual peptide MS/MS spectra with 
Mascot scores below 40 were checked manually and either interpreted as 
valid identifications or discarded. Typical contaminants, also present in 
immunopurifications using beads coated with pre-immune serum or antibodies 
directed against irrelevant proteins were omitted from the table. The proteins 
identified were further analyzed with the Ingenuity Pathway Analysis Software 
(Ingenuity Systems, Inc., USA) and clustered according to their involvement in 
different biological functions. The enriched categories obtained were 
represented according to their p-value. 
CHROMATIN IMMUNOPRECIPITATION (CHIP) 
5x108 ECs were fixed with 1 % formaldehyde for 10 min at 37 ºC and 
subjected to quantitative ChIP analysis as previously described [29]. Briefly,   
5 µg of the specific antibodies were pre-bound overnight, at 4 ºC, to protein     
G-Dynal magnetic beads (Invitrogen Corporation, USA), added to the diluted 
sonicated chromatin (4x 20 s, 50% output in Soniprep 150, Sanyo) and 
immunoprecipitated overnight, at 4 ºC. Antibodies used were as follows: 
VEGFR2 (Cell Signaling Tecnology, Inc., USA), Sp1 (Santa Cruz 
Biotechnology, USA), RNA Polymerase II (Covance, USA) and Rabbit/Mouse 
IgG (Santa Cruz Biotechonology, USA).  
The magnetic bead-chromatin complexes were collected and washed in RIPA 
buffer (containing 50 mM HEPES pH 7.6, 1 mM EDTA, 0.7 % Na 
deoxycholate, 1 % NP-40, 500 mM LiCl). Chromatin-protein complexes were 
further washed in 1x TE buffer, eluted from beads in 1 % SDS,                    
100 mM NaHCO3 and heated overnight at 65 ºC to reverse the formaldehyde 
cross-linking. DNA fragments were purified with a QIAquick Spin Kit (QIAGEN, 
Germany). The DNA amount of VEGFR2 gene immunoprecipitated was 
quantified by RT-PCR using primers designed for the amplification of the 
VEGFR2 proximal promoter (-300/-159 relative to the transcription start site). 
The primers used were as follows: 5’ CCGGCAAGCGATTAAATCTTGGAG 3’ 
(sense) and 5’ TTTCCCCACACAACTGGACTGC 3’ (antisense). Additionally 
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were used primers for the amplification of an intergenic region in chromosome 
10 as described [30]. The PCR reaction mixture used was as follows for a     
25 µl total volume: 1x SybrGreen (Applied Biosystems, USA), 100 nM of each 
primer, and 2.5 µl of each ChIP DNA sample (input 1:10). All reactions were 
performed and analysed as triplicates using a Fast 7500 Real time PCR 
(Applied Biosystems, USA). The results were normalized based on the 
{Delta}{Delta}Ct method as previously described [29,30,31]. Briefly, the 
threshold cycles (Ct) from total input samples were subtracted from the Ct of 
the IgG control and from the experimental IP (VEGFR2, Sp1 and RNA Pol II). 
The fold difference between the corrected value for the total input and 
corrected experimental IP value was calculated as 2{Delta}{Delta}Ct. The fold 
difference over background obtained for VEGFR2 promoter was further 
normalized to the value obtained for the intergenic region.  
QUANTITATIVE RT-PCR 
Total RNA and cDNA were prepared and quantitative RT-PCR (qRT-PCR) 
was performed as described [12]. VEGFR2 primer sequences were as follows: 
5’ ATTCCTCCCCCGCATCA 3’ (sense) and 5’ GCTCGTTGGCGCACTCTT 3’ 
(antisense). Sp1 primer sequences were as follows: 5’ TCGGATGAGCTACAG 
AGGCACAAA 3’ (sense) and 5’ AAAGTGCCCACACTCAGAGCTACA 3’ 
(antisense). 
ELECTROFORETIC MOBILITY SHIFT ASSAYS (EMSA) AND IMMUNODEPLETING 
EMSA (IDEMSA) 
The oligonucleotides including consensus recognition sequence for TFs YY1, 
NF%B and Sp1 are derived from Transcruz gel shift oligonucleotides 
(SantaCruz Biotechnology, USA). A DNA probe comprising the same region of 
the VEGFR2 promoter (-300/-159) amplified in ChIP assays was also used. 
EMSA were performed following standard methodology as described [9]. 
Probes were labeled with !-ATP 32P (Perkin Elmer, USA) and incubated for 
20 min at room temperature with 10 µg of EC nuclear extracts in a binding 
buffer (containing 10 mM HEPES, 4% Ficoll, 70 nM NaCl, 2 mM DTT,         
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100 µg/mL bovine serum albumin and 0.01% NP40). For competition assays, 
a 100-fold molar excess of unlabeled probe was incubated in the binding 
reaction. For supershift assays, 1 µg of the p65 or YY1 antibodies were added 
to the binding reaction for an additional 30 min at room temperature. DNA-
protein complexes were resolved in 5 % non-denaturating polyacrilamide gels. 
IDEMSA were performed as described [32]. Briefly, 30 µg of EC nuclear 
extracts were depleted of VEGFR2 by immunoprecipitation with anti-human 
VEGFR2 antibody for 1 h followed by incubation with sepharose beads for an 
additional hour, at 4 ºC. After centrifugation, 10 µg of the VEGFR2 
immunodepleted supernantant were used for each reaction of 
EMSA/Supershift as described above.  
LUCIFERASE REPORTER ASSAYS 
The proximal promoter of VEGFR2 gene was amplified from genomic DNA by 
PCR and cloned into a pGL3-promoter firefly luciferase vector (Promega 
Corporation, USA). Briefly, the sequence from -300/+1 of the VEGFR2 
proximal promoter was amplified using oligonucleotides with flanking 
restriction enzyme sites 5’ XhoI and 3’ BglII. The primers sequences were as 
follows: FW: 5’ AAGCTCTCGAGGGTTAATTAAGACCGGCAAGCGATTAAAT 
CTTGGAG 3’; RV: 5’ AGATCTTTAGATCTGTAGCAGGGTGGGAGCTGGTG 
CCGA 3’. A deletion fragment of the region from %116/+1 bp of the VEGFR2 
promoter was obtained using the same procedure. The primer sequence was 
as follows: FW: 5’ AGCTCTCGAGGGTTAATTAAGGTACCCGGGTGAGGGG 
CCGGGCT 3’. All constructs were confirmed by DNA sequencing. For 
luciferase reporter gene assays, NIH 3T3 GFP and NIH 3T3 VEGFR2-GFP 
expressing cells growing in 24-well plates were co-transfected with 400 ng of 
pGL3 control or pGL3 VEGFR2 (-300/+1) or pGL3 VEGFR2 (-116/+1) and    
40 ng of the pCMV-"gal (Clontech Laboratories, Inc., USA) using the Fugene 
6 transfection reagent (Roche Applied Science, USA). 24 h post-transfection, 
cells were harvested and luciferase activity was measured using Luciferase 
Assay Reagent (Promega Corporation, USA). "-galoctosidase activity was 
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measured using Trophic Reagent (Applied Biosystems, USA). Results were 
normalized by dividing the luciferase activity values for "-galoctosidase activity 
values and represented as relative luciferase activity. Data are mean ± s.e.m. 
of triplicates and represents three independent experiments. 
STATISTICAL ANALYSIS 
Data are represented as the mean ± s.e.m., and statistical analysis was 
performed with Student’s t test. A p value < 0.05 was considered statistically 
significant. 
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4.8. SUPPLEMENTARY RESULTS  
VEGFR2 AND SP1 KNOCKDOWN USING SIRNA 
We experimentally reduced the expression of VEGFR2 and Sp1 using siRNA 
technology. A pool of VEGFR2 siRNA oligos effectively abrogated the 
VEGFR2 expression by 70% compared with the scrambled siRNA, in ECs as 
evaluated by qRT-PCR (Figure S1A). Similar results were obtained using a 
pool of Sp1 siRNA oligos and compared to scrambled siRNA (Figure S1B). 
 
Figure S1. VEGFR2 and Sp1 relative gene expression is decreased after VEGFR2 or Sp1 siRNA 
transfection.  
ECs were transfected with scrambled siRNA, VEGFR2 siRNA or Sp1 siRNA and 24 h later the (A) 
VEGFR2 or (B) Sp1 mRNA was quantified by qRT-PCR. Data are mean ± SD and represents the fold 
change in VEGFR2 or Sp1 gene expression relative to the internal calibrator (scrambled siRNA) in 
triplicates measurements and are representative of three independent experiments. 
VEGFR2 AND SP1 ARE PRESENT IN THE SAME PROTEIN/DNA COMPLEXES 
We have observed in EMSA assays that VEGFR2-immunodepleted nuclear 
extracts failed to form the C2 complex and showed a decreased intensity in C1 
complex (please see Figure 4D). These results confirmed the presence of 
VEGFR2 in the DNA/protein complexes established with the VEGFR2 
promoter region analyzed in the EMSA experiments. The VEGFR2 depletion 
was confirmed by Western-blot analysis (Figure S2A).  
Furthermore, we confirmed that these results were specific, since the same 
experiment using IgG immunodepleted extracts had no effect in the intensity 
of the complexes observed (Figure S2B). Also, we observed that Sp1-
depleted extracts showed a decreased intensity in the complexes C1 and C2, 
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confirming that both VEGFR2 and Sp1 are present in the same DNA/ protein 
complexes in the promoter region of VEGFR2 analyzed (Figure S2B). 
 
Figure S2. Sp1 and VEGFR2 are present in the same protein/DNA complexes.  
(A) Immunoprecipitation (IP) of 30 µg EC nuclear extract with anti-human VEGFR2 were analyzed by 
Western-blot. The immunodepleted extract (ID VEGFR2) and Input were also included as control. (B) 
EMSA analysis of the VEGFR2 promoter with IgG-immunodepleted (ID Rabbit IgG) (lane 3) or Sp1-
immunodepleted (ID Sp1) extracts were conducted. As a positive control EC nuclear extracts (lane 2, 
5) were also evaluated. Four complexes (C1-C4) are indicated with black arrows. Control lanes 1 and 4 
contain only the radiolabeled probe. 
VEGFR2 BINDING TO ITS OWN PROMOTER IS INDEPENDENT OF EGFR ACTIVATION  
Our previous results showed that VEGFR2 activation by VEGF is crucial for 
VEGFR2 binding to its own promoter in vivo. We showed that both 
Bevacizumab, and Sunitinib, led to a strong reduction of the binding of 
VEGFR2 to its own promoter, further supporting this idea. To further validate 
the specific effect of the VEGFR2 inhibitors on the VEGFR2 DNA binding, we 
tested the effect of an epidermal growth factor receptor-tyrosine kinase 
inhibitor, Iressa in ECs, by quantitative ChIP. Our results showed no diference 
in the DNA binding of VEGFR2 to its own promoter in the presence or 
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absence of Iressa further supporting the specific effect of the VEGFR2 
inhibitors used previously (Figure S3). 
 
Figure S3. VEGFR2 binding to its own promoter is independent of EGFR activation. 
ChIP assays of the VEGFR2 proximal promoter were performed using ECs cultured in growing media 
and treated or not with 0.1 µM Iressa for 16 h. Ethanol was used as vehicle in the control cells. ChIP 
values are relative to control IgG background and normalized to an intergenic region. Data are mean ± 
s.e.m. of triplicates and represents three independent experiments. 
VEGFR2 PUTATIVE INTERACTIONS IN THE NUCLEUS OF ECS 
The proteins identified by MS as putative interacting partners with nuclear 
VEGFR2 with a Mascot score greater than 200 are listed in Table S1 
(Appendix A). The most significant results analyzed above (Figure 3B) with 
IPA software refer to proteins involved in gene expression such as, 
Transcription intermediary factor 1 " (TRIM28), Nucleolysin TIAR (TIAL1), 
TATA element modulatory factor (TMF1), Myb-binding protein 1A (MYBBP1A) 
or AT-rich interactive domain-containing protein 4A (ARID4A), among others.  
Other proteins involved in DNA replication, recombination, and repair such as, 
Breast cancer type 1 susceptibility protein (BRCA1) and Serine-protein kinase 
ATM (ATM), were also identified. In the future these results will be confirmed 
by western blot on VEGFR2 immunoprecipitates. 
Our results also suggest the involvement of VEGFR2 in RNA post-
transcriptional modifications as putative interactions with splicing factors 
U2AF35 and U2AF65 were identified in our MS analysis. However, we were 
unable to confirm an interaction between VEGFR2 and these factors in 
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VEGFR2 immunoprecipitates (Figure S4A). Also, the presence of VEGFR2 
was not observed in U2AF65 immunoprecipitates (Figure S4B). 
 
Figure S4. VEGFR2 does not interact with U2AF35 and U2AF65.  
(A) Immunoprecipitation (IP) of 1 mg EC nuclear extract was conducted with anti-human VEGFR2 
followed by western blotting using the anti-human VEGFR2, anti-human U2AF65 (Sigma-Aldrich) and 
anti-U2AF35 (ProteinTech Group, Inc., USA) antibodies. VEGFR2 antibody plus beads (without N) 
were used as negative control for immunoprecipitation. 100 µg of non-immunoprecipitated EC nuclear 
extract were included as control. (B) Immunoprecipitation (IP) of 1 mg EC nuclear extract was 
conducted with anti-human U2AF65 followed by western blotting using the anti-human VEGFR2 and 
anti-U2AF65. U2AF65 antibody plus beads (without N) were used as negative control for 
immunoprecipitation. 100 µg of non-immunoprecipitated EC nuclear extract (Input) were included as 
control. 
VEGFR2 NUCLEAR LEVELS ARE ASSOCIATED WITH DIFFERENTIAL 
TRANSCRIPTIONAL PATTERNS 
We showed that EC transcription levels correlate with VEGFR2 nuclear 
accumulation (please see Figure 2C and 2D). Based on these results, we 
investigated if VEGFR2 nuclear accumulation could also be correlated with 
changes in the DNA binding activity of transcription factors (TFs) involved in 
cell growth. 
With this objective, ECs were treated with 6.12 Ab or KDRi, since we showed 
that ECs cultured in the presence of these agents present decreased VEGFR2 
nuclear levels compared to untreated cells. The respective nuclear cell 
extracts were used to screen the profile activities of several TFs by performing 
a “TranSignal Protein/DNA Array Cell Growth” (Panomics, USA). Briefly, the 
nuclear extracts were incubated, in a binding buffer, with a set of biotinylated 
probes comprising DNA binding consensus sequences for the TFs analyzed 
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(Figure S5A, left panel), allowing the formation of DNA/protein complexes. 
Next, the DNA/protein complexes formed were purified from the free probes 
and hybridized to the TranSignal array membrane. The results were detected 
by HRP-based chemiluminescence according to the manufacture’s 
instructions and quantified using ImageJ software (NIH, USA). The results 
were expressed as a ratio between 6.12Ab or KDRi and control. We observed 
that the majority of the TFs analyzed, such as c-Myb, CREB, E2F1, EGR, 
FKHR, YY1, NF%B, pax-2 and pax-3, showed a significantly increased DNA 
binding activity (> 2 fold), in cells treated with 6.12 Ab or KDRi (Figure S5B). 
Surprisingly, these results do not reflect the results obtained with the 5-FU 
incorporation assay, suggesting that in the same culture conditions, these TFs 
are differently modulated compared to the general transcription reduction 
observed before. To confirm the results obtained from our TranSignal array, 
we performed EMSA, using the same nuclear extracts (Figure S5C, S5D and 
S5E). Briefly, we analyzed the DNA binding activity of CREB (Figure S5C), 
YY1 (Figure S5D) or NF%B (Figure S5E) using a DNA radiolabeled probe 
comprising the consensus binding sequences of each of these TFs incubated 
with the nuclear extracts obtained above.  
We observed a slight increase in the DNA binding of CREB, YY1 and NF%B in 
cells treated with 6.12 Ab (Figure S5C, S5D and S5E). We were unable to 
observe a significant change in the DNA binding activity for these TFs in cells 
treated with KDRi (Figure S5C, D and E). Taken together, the results obtained 
with the EMSA do not confirm the results obtained with the TranSignal array. 
Since we used the same nuclear extracts, we expected to obtain similar 
results. Following the loss of consistency in the results, both technical 
approaches should be repeated using other nuclear extracts. However, both 
approaches imply significant costs. Moreover, the results obtained here are 
the consequence of ECs treated with agents that may have undesired effects 
in other cell targets. Therefore, the apparent contradictory results may also be 
due to indirect effects in unidentified molecular targets, making it difficult to 
interpret the results. For these reasons, we developed a different approach to 
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modulate the VEGFR2 nuclear accumulation in ECs. ECs overexpressing 
VEGFR2 and several tyrosine point mutants were generated. 
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Figure S5. The activity and expression of several transcription factors (TFs) is modulated with 
the nuclear accumulation of VEGFR2. 
Nuclear extracts were prepared from ECs cultured in growing media conditions and treated with 6.12 
Ab (1 µg/ml) or KDRi (70 nM) for 24 h or left untreated (control). 25 µg of nuclear extract from each 
condition were used for the “TranSignal Protein/DNA Array Cell Growth” (Panomics, USA). (A) 
Schematic diagram of the array membrane (left panel). Each spot contains the specific DNA consensus 
binding sequence for the TF indicated and in duplicate. The grey spots for each indicated TF contain 
the same DNA sequence diluted 1:10. The grey columns on the right and bottom sides are spotted with 
biotinylated DNA and were used for alignment of the membranes (Adapted from manufacturer 
protocol). The TFs activities profiles for the experimental conditions tested – “Control”, “6.12 Ab” and 
“KDRi” at 15 s exposure (right panel). (B) The intensity of each spot in the three membranes was 
quantified using Image J and normalized for the background intensity. The TF DNA binding activities 
obtained for the three conditions were compared and represented as the ratio between 6.12 Ab and 
control (left panel) or ratio between KDRi and control (right panel). (C-E) The DNA binding activity of 
CREB (C), YY1 (D) or NF%B (E) was confirmed by EMSA experiments using 10 µg of the same EC 
nuclear extracts used in the array. Nuclear extracts from control (lanes 2,8,15), 6.12 Ab (lanes 3,9,16) 
or KDRi (lanes 4,10,17) were incubated with CREB (C), NF%B (D) or YY1 (E) radiolabeled probes. Two 
CREB complexes (C1-C2), five YY1 complexes (C1-C5) and two NF%B (C1-C2) are indicated with 
black arrows. Specific anti-P-CREB (lane 5), anti-YY1 (lane 13), anti-p65 (lane 18) or anti-c-rel (lane 
19) were introduced in the binding reaction to analyze the appearance of a supershift complex. A 
competitive assay using 100x excess of cold probe of CREB (lane 6), YY1 (lane 11) or NF%B (lane 20) 
was performed. Control lanes 1 and 6 contain only the radiolabeled probes. 
VEGFR2 DNA BINDING IN ECS IS NOT POTENTIATED DURING HYPOXIA 
We have described above the VEGFR2 nuclear translocation and DNA 
binding activity upon VEGF stimulation. Since VEGF expression is 
upregulated during hypoxia [1], we tested if in these conditions, the VEGFR2 
DNA binding is potentiated. Our hypothesis is that the increased VEGF 
expression could result in increased VEGFR2 activation and consequently, 
increased VEGFR2 DNA binding activity. Accordingly, we analyzed by 
quantitative ChIP the VEGFR2 DNA binding activity of ECs cultured in growing 
media conditions and treated with cobalt chloride (CoCl2- chemically 
mimetizes hypoxia by stabilization and activation of HIF proteins), (Figure S6). 
We observed that under hypoxic conditions, the VEGFR2 DNA binding was 
not significantly increased, when compared to control normoxic conditions 
(Normoxia – 4.81±0.84 vs Hypoxia – 5.14±0.62).  
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Figure S6. VEGFR2 DNA binding is not significantly increased during hypoxia.  
ChIP assays of the VEGFR2 proximal promoter under hypoxic conditions were performed using ECs 
cultured in growing media and left untreated or treated with 150 µM CoCl2 for 36 h. Antibodies against 
VEGFR2 and Sp1 were used. Normal rabbit/mouse IgG were used as control. Also, an antibody 
against human RNA Polymerase II was used to test the promoter activity. All values are relative to 
control IgG background and normalized to an intergenic region. Data are mean ± s.e.m. of triplicates 
and represents three independent experiments 
Our results also showed that Sp1 DNA binding was decreased in hypoxia 
when compared to normoxia culture conditions (Normoxia – 9.62±2.25 vs 
Hypoxia – 1.76±0.48). However, to confirm these results, it would be required 
to measure the VEGF levels after CoCl2 treatment. A 4 fold increased VEGF 
expression was reported with 150 µM CoCl2 [2]. It would also be interesting to 
analyze VEGFR1 expression in the same culture conditions since it was 
reported that not only VEGF but also VEGFR1 gene expression is directly 
upregulated in ECs exposed to hypoxia [3]. This suggests that although the 
VEGF levels might be increased under these hypoxic conditions, and therefore 
an increased VEGFR2 activation/nuclear translocation is expected, VEGFR1 
levels might also be increased, suggesting that VEGF sequestration and 
consequently a lower VEGF accessibility to VEGFR2 might occur. 
It has not been identified a HIF regulatory element in the VEGFR2 promoter 
region [3], and the transcriptional VEGFR2 expression was not changed in 
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ECs exposed to hypoxia [3]. Therefore, a direct hypoxic-mediated effect in 
VEGFR2 expression was not expected. 
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The canonical mode of action of receptor tyrosine kinases (RTKs) considers 
that the activation of these receptors by specific ligands at the cell surface 
leads to the modulation of signal transduction cascades that elicit a variety of 
biological functions [1]. In this study, we show that the biological function of 
VEGFR2 might involve a novel activity that requires its internalization to the 
nucleus, in addition to this canonical mechanism. Our results strongly suggest 
that VEGFR2 might act as a transcription factor and that it is involved in the 
regulation of its own transcription in a possible positive feedback loop that 
might be important for maintaining VEGFR2 signaling in activated cells, 
amplifying the angiogenic response. 
Whether nuclear VEGFR2 is also involved in the transcriptional regulation of 
other genes remains to be determined. Our MS results suggest that potential 
VEGFR2 partners in the nucleus are proteins involved in the regulation of 
gene expression and DNA repair, among others. Also, the expression or 
transcription factor activity of different nuclear proteins was increased in ECs 
over-expressing VEGFR2, which correlated with the increased levels of 
VEGFR2, further suggesting that the transcriptional activity of VEGFR2 might 
be extended beyond its own regulation. 
Additionally, several studies have documented the presence of VEGFR2 or its 
ligand VEGF not only at cell surface but also in the nucleus. In particular, it 
was observed the nuclear internalization of VEGF in bovine adrenal cortex 
ECs following in vitro wounding [2]. Also, nuclear VEGFR2 was observed in 
normal and neoplastic renal tissues [3,4], in the nucleus of MCF-7, HeLa and 
HL60 cells [4] and in bovine and rat EC [5,6]. Similar findings were reported in 
studies showing that VEGFR2 is constitutively phosphorylated and located at 
the nucleus of VEGF-producing leukemias [7,8]. These results further suggest 
a specific and important role for VEGF/VEGFR2 in the nucleus. 
Our findings suggest a dual mechanism for the biological activity of this 
receptor. One of them involves the canonical signaling pathway represented 
by the triggering of signal transduction cascades upon activation of VEGFR2 
by VEGF at the membrane [1]. The second mechanism would be mediated by 
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the internalization of the activated receptor and the regulation of gene 
expression. The balance between these two activities is probably required 
during physiological and pathological events. 
The recognition of VEGFR2 as a membrane protein, playing a critical role in 
tumor angiogenesis, has led to the development of different anti-angiogenic 
strategies [9]. However, the existence of mechanisms for evasive resistance to 
anti-VEGF therapy has been demonstrated [10,11]. In particular, it was shown 
that an anti-VEGFR2 blocking antibody (DC101 Ab, ImClone) promotes tumor 
re-growth in mice, after an initial period of growth repression [10] and an 
invasive phenotype remained augmented after termination of therapy, 
contributing to the evasive resistance to the anti-angiogenic therapy [11].  
However, we must consider that in tumor cells, VEGFR2 therapy inhibits the 
signaling mediated by the membrane VEGFR2 [12]. The effects in the nuclear 
translocation of VEGFR2 were not studied. Because we have shown that a 
neutralizing antibody against VEGFR2 (IMC-1C11 Ab, ImClone) failed to block 
VEGFR2 nuclear translocation, the effect of these therapies on the nuclear 
activity of VEGFR2 must now be considered.  
Based on these data, we may hypothesize that the nuclear role of this 
angiogenic factor may be involved in the resistance to anti-VEGF therapy. 
In addition to VEGFR2, other RTKs might share this dual signaling 
mechanism. Evidence has been collected in the last years showing the 
presence of several RTKs, such as EGFR, FGFR in the cell nucleus and that 
these receptors also have transcriptional activity [13,14,15], as we describe 
here for VEGFR2. Interestingly, it was shown that cells with acquired 
resistance to Cetuximab (a neutralizing antibody against epidermal growth 
factor receptor (EGFR), [16]) have a constitutive translocation of EGFR to the 
nucleus [17]. This suggests that the nuclear expression of EGFR may be a 
critical determinant for resistance to therapy [17].  
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INTERACTION WITH VEGFR1 IS IMPORTANT FOR THE NUCLEAR INTERNALIZATION 
OF VEGFR2  
Several studies have suggested different roles for VEGFR1 and VEGFR2 [18]. 
In particular, the affinity of VEGF is higher for VEGFR1 than for VEGFR2 [9], 
but in contrast to VEGFR1, VEGFR2 has a potent tyrosine kinase activity and 
is considered the major mediator of the signaling responses induced by VEGF 
[9]. Based on the biochemical and genetic data it was proposed that VEGFR1 
could be a negative regulator of the VEGF activity, acting as a “decoy” 
receptor to sequester VEGF, thus rendering it less available for interacting 
with VEGFR2 [19].  
We now show that VEGFR1 is also important for VEGFR2 internalization 
(Figure 1). This is supported by our results showing that neutralizing agents 
against VEGFR1 efficiently blocked VEGFR2 nuclear translocation. 
Furthermore, we showed that activation of VEGFR1 alone, through the use of 
PlGF, results in VEGFR2 phosphorylation by a mechanism inhibited by the 
6.12Ab and KDRi.  
The interaction between the two receptors induces VEGFR2 phosphorylation 
[20], which, as will be discussed below, is important for the internalization 
process. The ability of activated VEGFR1 to induce intermolecular trans-
phosphorylation of VEGFR2, increasing VEGFR2 phosphorylation, has been 
previously reported [20] and is consistent with the functional interaction 
between the two receptors. However, while this interaction seems to be clear 
[20], the mechanism for the trans-activation mediated by VEGFR1 remains to 
be fully explained. Autiero and collegues [20] reported two alternative crosstalk 
mechanisms between the two VEGF receptors. One of them is the trans-
activation of VEGFR2 homodimers by VEGFR1 homodimers [20], which 
suggests that this crosstalk may not be direct. Indeed, it was previously 
suggested that intermediate signaling molecules such as PI3K, PKC or MAPK 
might be involved in this process, either by stimulating intrinsic kinase activity 
of VEGFR2 or by suppressing an associated tyrosine phosphatase [5,20]. 
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Figure 1. Schematic representation of the VEGF-VEGFR2 nuclear internalization in ECs. 
In the presence of VEGF, both VEGF and VEGFR2 are internalized to the cell nucleus in a VEGFR1-
dependent process. This mechanism requires the activation of PI3K pathway and involves a caveolin-1 
mediated endocytosis and the microtubules. In the nucleus, VEGFR2 interacts with Sp1 transcription 
factor and binds to an Sp1-responsive region in the VEGFR2 proximal promoter. 
Consistent with this indirect mechanism, we showed that treatment with a 
PI3K inhibitor blocked VEGFR2 internalization, suggesting that PI3K might 
mediate the VEGFR2-trans-phosphorylation induced by VEGFR1, which is 
required for the VEGFR2 nuclear internalization process (Figure 1). The 
second crosstalk mechanism proposed suggests that PlGF/VEGF 
heterodimers or VEGF homodimers can induce the formation of 
VEGFR1/VEGFR2 heterodimers in which the trans-phosphorylation of each 
monomer was observed [20], which is consistent with a more direct trans-
activation mechanism. In our study we cannot exclude the contribution of both 
crosstalk mechanisms to the internalization of VEGFR2. However, if the 
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activation of VEGFR2 internalization requires heterodimerization with 
VEGFR1, the physical interaction between the two receptors must be then lost 
because in all the culture conditions tested, VEGFR1 was always located at 
the cell surface. 
The requirement of the VEGFR crosstalk for VEGFR2 nuclear internalization 
seems to be in contradiction with the analysis of mutant mice carrying a 
truncated VEGFR1 that lacks the tyrosine kinase domain. Vegfr1TK!/! mice are 
viable and fertile and do not exhibit deficiencies in vascular development, 
indicating that the VEGFR1 tyrosine kinase activity is dispensable for 
embryonic angiogenesis [21]. However, it was described that growth of 
VEGF/PLGF-dependent-Lewis lung carcinomas (LCC), was retarded in 
Vegfr1TK!/! mice compared to wild-type mice [22]. This finding could indicate 
that the functional crosstalk between the two VEGF receptors and 
consequently, VEGFR2 nuclear translocation might be required under certain 
pathological circumstances, such as tumor growth. In the future, it would be 
important to analyze the subcellular localization of VEGFR2 in the blood 
vessels associated with these tumors to test if the retarded tumor growth is 
correlated with a decreased nuclear internalization of the receptor. This could 
further suggest the involvement of the nuclear activity of VEGFR2 in the 
evasive resistant mechanisms against anti-angiogenic therapy. 
VEGFR2 PHOSPHORYLATION – THE DRIVING FORCE FOR NUCLEAR 
TRANSLOCATION  
The VEGF or VEGFR1-mediated activation of VEGFR2 induces the 
phosphorylation of several tyrosine residues in the intracellular region that are 
required for the functional activity of VEGFR2 [18,20]. We showed that 
tyrosine phosphorylation of VEGFR2 is also essential for the internalization 
process (Figure 1). Several findings described in this work support this idea. In 
particular, we showed that VEGFR2 mutants with deleted kinase and            
C-terminal tail domains have impaired nuclear internalization. Furthermore, 
Bevacizumab or Sunitinib, two anti-angiogenic drugs that inhibit VEGFR2 
phosphorylation, blocked the binding of VEGFR2 to its own promoter. This 
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result is consistent with the requirement of tyrosine phosphorylation for 
VEGFR2 internalization and its subsequent transcriptional activity. 
Although, both activation of signal transduction pathways and nuclear 
internalization require the phosphorylation of VEGFR2, molecular analyses 
indicate that the tyrosine residues involved are different. Our experiments 
showed that internalization of VEGFR2 requires phosphorylation of Y951 
located in the kinase-insert domain (Figure 1). Conversely, the tyrosine 
residues Y1054 and Y1059 located in the kinase catalytic domain, which have 
been described as required for maximal VEGFR2 kinase activity in vitro [23], 
seemed to be dispensable for the internalization process. Interestingly, it has 
been reported that a tyrosine kinase-inactive VEGFR2 can be phosphorylated 
by VEGFR1 in tyrosine residues other than Y1054/1059 [20]. As internalization 
of VEGFR2 is dependent of VEGFR1-mediated phosphorylation, this 
observation further supports that the activation of these residues is not 
required for the internalization process.  
Although the importance of the activation of tyrosine Y951 residue has not 
been evaluated in animal models, it has been shown that in sprouting 
embryonic body (EB) vessels the phosphorylation of tyrosine Y951 is 
enhanced compared to resting vessels, suggesting that activation of this 
residue might be required for EC migration mediated by VEGFR2 [24]. These 
observations are consistent with our data showing that ECs expressing 
VEGFR2(Y951/996F)-GFP mutant have a decreased migratory response 
compared to control ECs expressing VEGFR2(WT)-GFP. Since the 
phosphorylation in Y951 seems to be associated with the nuclear 
internalization of VEGFR2, these results might indicate that the nuclear activity 
of this receptor is probably associated with EC migratory properties. Indeed, 
this observation is consistent with our results showing that following wounding 
in vitro, there is a rapid nuclear internalization of VEGF and VEGFR2 in ECs at 
the wound edges that is not observed in ECs far from the wound. Furthermore, 
the blockage of the VEGFR1-mediated VEGFR2 nuclear translocation led to a 
delayed EC recovery following injury. This effect correlates with a lack of 
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internalization of VEGF and VEGFR2, further suggesting a functional 
relevance for the nuclear translocation of VEGF and VEGFR2.  
Genetic studies in mice expressing the VEGFR2 (Y951F) mutant will be useful 
to evaluate the requirement of phosphorylating tyrosine Y951 for the nuclear 
internalization of VEGFR2 and for the biological activity of this receptor. 
VEGF AND VEGFR2 – FROM THE MEMBRANE TO THE NUCLEUS  
The mechanism by which an integral membrane protein translocates to the 
nucleus remains largely unanswered. Different mechanisms have been 
proposed to explain the nuclear transport of other membrane RTKs [15]. The 
best-studied case is the nuclear translocation and activity of EGFR. The most 
accepted proposed mechanism suggests that the route for the nuclear 
translocation of EGFR involves a clathrin-mediated endocytosis and the 
retrograde transport after endocytosis through membrane compartments such 
as the Golgi apparatus and the endoplasmic reticulum (ER) [15].  
In the case of VEGFR2, a number of observations indicate that nuclear 
translocation might involve a caveolae-mediated endocytosis mechanism. 
First, VEGFR2 seems to interact with components of this endocytic pathway. 
We have shown that the VEGF-VEGFR2 complex interacts with caveolin-1 in 
the cytoskeletal fraction of ECs (Figure 1). Other reports showed that VEGFR2 
colocalizes in the perinuclear area with both caveolin-1 and with dynamin-2, a 
GTPase involved in receptor-mediated endocytosis [25]. In addition, it was 
recently reported that dynamin-2 inhibitors blocked the VEGF-induced 
internalization of VEGFR2, resulting in decreased tip EC filopodial extensions 
[26]. Furthermore, we have shown that drugs inhibiting microtubule 
polymerization, such as nocodozole, blocked the internalization of the VEGF-
VEGFR2 complex. Interestingly, caveolae are transported from the membrane 
to intracellular organelles along microtubules [27], and dynamin-2 seems to 
require interactions with functional microtubules to stimulate its GTPase 
activity and promote vesicular transport [28,29,30,31]. In this context, our 
finding that VEGFR2 fails to internalize upon microtubule depolymerization is 
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consistent with the involvement of caveolae in the internalization of this 
receptor (Figure 1). 
It has been suggested that the internalization of VEGFR2 could also be 
mediated by clathrin-dependent endocytosis at cell junctions, in the absence 
of VE-Cadherin [32]. Importantly, even through this pathway VEGFR2 retains 
its signaling activity when internalized to intracellular endosomes [32]. 
Clathrin-dependent internalization has been described for EGFR, where it 
seems to be associated with receptor turnover, either by recycling it to the 
membrane or for targeting it for degradation in a c-Cbl-dependent manner [33]. 
We cannot exclude that both clathrin and caveolar-dependent endocytosis 
might be responsible for the VEGFR2 internalization in ECs. Indeed, a similar 
c-Cbl dependent mechanism has been described for VEGFR2 [34], although it 
remains controversial since other reports suggested that c-Cbl is not involved 
in VEGFR2 degradation [35]. Consistent with the second report, we were 
unable to observe an interaction between VEGFR2 and c-Cbl in ECs. 
In addition to its detachment from the cell membrane, the nuclear translocation 
of VEGFR2 requires the receptor to be transported from the cytoplamic 
vesicles into the nuclear compartment. The mechanism for this transportation 
is not clear but seems to require the nuclear pore complex (NPC), (Figure 1). 
Our finding that drugs inhibiting the NPC induced accumulation of VEGF and 
VEGFR2 in the perinuclear region supports this conclusion. Furthermore, our 
FRAP analysis of the nuclear internalization dynamics of VEGFR2-GFP in 
ECs also suggested an active transport of VEGFR2 from the cytoplasm to the 
nucleus, which is consistent with the involvement of the NPC in this process. 
The typical mechanism for the import of proteins through the NPC is mediated 
by the binding of the protein nuclear localization signals (NLS) to importin # 
and " to form a complex that interacts with the NPC so that the protein can 
enter the nucleoplasm [36].  
However, the presence of NLS in the VEGFR2 sequence was neither 
described in the literature nor identified in the bioinformatics analyses 
performed by us. The proposed model for FGFR1 internalization could 
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suggest a solution for this apparent paradox. FGFR1, which is also devoid of a 
NLS sequence, is chaperoned to the nucleus by its ligand FGF2 that harbors 
NLS sequences, inducing their nuclear translocation in an importin "-
dependent manner [37]. VEGF has five potential NLS sequences in the         
C-terminal region [2] and it is possible that the VEGF-NLS sequences drive 
the complex VEGF-VEGFR2 through the NPC to the nucleus. Consistent with 
this hypothesis, we found that VEGF and VEGFR2 are transported together as 
a complex. Further analysis of interactions between VEGF and VEGFR2 with 
importins and their contribution to this process will be required to fully 
understand the internalization process. Additionally, experiments using a 
VEGFR2 construct fused to NLS sequences could further illustrate the 
contribution of VEGF in this internalization process. 
The subcellular localization of the VEGF-VEGFR2 complex, including the 
presence of both proteins in the nucleus, is a dynamic process. This is 
supported by the fact that during a time course of 7 h after VEGF stimulation, 
the levels of nuclear VEGFR2 protein undergo variations. Moreover, after 
performing a wound, our results also suggest that the VEGF/VEGFR2 nuclear 
internalization is associated with a dynamic process according to a 
physiological response. VEGF and VEGFR2 are rapidly internalized in ECs 
close to the wound edge (as early as 15 min post-wounding) and decreases 
upon EC recovery. Taken together, these results support the existence of a 
dynamic process that controls the levels of VEGF and VEGFR2 in the nuclear 
compartment.  
VEGF-VEGFR2 complexes are also actively exported from the nucleus back 
to the cytoplasm/cell surface. The majority of the proteins shuttling from the 
nucleus to the cytoplasm use a nuclear export signal (NES)-CRM1 receptor 
dependent pathway [38], although the involvement of alternative mechanisms 
for nuclear export processes has been appreciated [39,40]. Our finding that 
VEGF is arrested in the nucleus upon leptomycin B treatment suggests that 
this molecule exit the nucleus following the classical export receptor-mediated 
mechanism [38]. Further studies will be required to identify possible NES 
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sequences in VEGF, as well as the recruitment of an export receptor such as 
CRM1. Interestingly, our results suggest that VEGFR2 is exported by a 
different mechanism, as its exit from the nucleus is not affected by leptomycin 
B.  
An alternative export mechanism has been described for Smad3, which is 
mediated by exportin 4 and requires Ran GTPase as a co-factor [40].  
Exportin 4, a member of the importin-family was described to recognize 
complex protein motifs in Smad3, resembling an export signal distinct from the 
well-characterized exportin 1 (CRM1)-dependent NES [40]. Whether this 
alternative nuclear export mechanism or another still not identified system is 
involved in the shuttling of VEGFR2 from the nucleus to the cytoplasm 
remains to be determined. The mapping of potential export motifs in the 
VEGFR2 sequence could help to elucidate the mechanisms that mediate the 
nuclear-cytoplasmic transport of the receptor. 
A major question that remains to be answered is how these transmembrane 
receptors can be released from the membranes of the intracellular organelles 
or vesicles and be transported to the nucleus. This was investigated for 
FGFR1. In this case, it was shown that this receptor has an atypical 
transmembrane domain, which interacts with pp90 ribosomal S6 kinase 1 
mediating its release from the membrane [41]. We do not expect a similar 
mechanism for VEGFR2 since this receptor has a typical hydrophobic 
transmembrane domain [1]. 
Another important question that remains unanswered is whether VEGF itself 
plays a role in the nucleus or if it is only required to mediate the internalization 
of VEGFR2. We have shown that the VEGF-VEGFR2 interaction during the 
internalization process is consistent with its contribution to this dynamic 
mechanism. However, in the nucleus this interaction is lost and their nucleo-
cytoplasmic export seems to require different pathways. A screening of the 
proteins that might interact with VEGF in the nucleus will be a first step to 
elucidate to this problem. 
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VEGFR2 IN THE NUCLEUS – A POTENTIAL TRANSCRIPTION FACTOR  
The function and relevance of VEGFR2 in the nuclear compartment of ECs 
was our main focus after defining the molecular basis of the internalization 
process. Our results clearly show that VEGFR2 has transcriptional activity, 
thus opening the possibility for an involvement of VEGFR2 in the regulation of 
a pro-angiogenic response in ECs at the transcriptional level. In this work we 
were able to establish that VEGFR2 binds and activates its own promoter 
(Figure 1). Our finding that the binding of VEGFR2 to its proximal promoter is 
dramatically increased in ECs cultured in the presence of VEGF further 
supports that this binding is directly linked to the activation of the receptor by 
VEGF. This is consistent with a functional relevance for this process. 
VEGFR2 regulation of its promoter apparently involves interactions with the 
Sp1, a transcription factor that has been described as a major regulator of 
VEGFR2 expression in ECs [42]. In particular, we have shown that Sp1 
directly interacts with the intracellular domain of VEGFR2 (789-1356 aa) by 
pull-down assays using purified proteins. Furthermore, we have shown that 
VEGFR2 binds to the Sp1-responsive region of the VEGFR2 promoter, 
suggesting a close interplay between Sp1 and VEGFR2 in the modulation of 
the VEGFR2 expression (Figure 1). This interaction was further supported by 
our EMSA experiments showing that VEGFR2 and Sp1 are present in the 
same protein-DNA complexes in the VEGFR2 promoter.  
Different studies focused on the role of Sp1 in angiogenesis showed that 
several of its target genes (e.g., VEGFR2, VEGF and Sp1) were upregulated 
in human pancreatic tumors, suggesting its involvement in tumor progression 
and metastasis [43,44]. In particular, it was shown that the combined 
treatment with bevacizumab (a neutralizing antibody against VEGF) and 
mithramycin A (an Sp1 inhibitor), suppressed more efficiently the expression 
of these angiogenic factors both in vitro and in tumors growing in nude mice 
[44]. Since we observed that treatment with Bevacizumab or Sunitinib blocked 
the VEGF-induced VEGFR2 DNA binding, we can speculate that the Sp1-
mediated expression of at least VEGFR2 gene is influenced by nuclear 
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VEGFR2. In this context, it will be important to better understand the 
interactions between VEGFR2 and Sp1 in the control of VEGFR2 expression. 
For instance, it will be important to understand whether both VEGFR2 and Sp1 
must simultaneously interact with the promoter to elicit upregulation of 
VEGFR2 expression or if any of the two factors can activate the promoter in 
the absence of the other. Clearly, experiments of sequential chromatin 
immunoprecipitations (ChIP-Re ChIP), using consecutively the VEGFR2 and 
Sp1 antibodies will help to elucidate these issues. 
Having shown that VEGFR2 regulates its own transcription, it is now important 
to know if the receptor is involved in the regulation of other genes and/or if it is 
directly involved in the regulation of different cellular responses in ECs. This is 
one of the most important future perspectives of this work and implicates novel 
lines of research. The identification of other VEGFR2 transcriptional targets 
will be extremely important to further understand the role of this receptor in the 
nucleus. The use of ChIP coupled with high-throughput sequencing analysis 
(ChIP-seq), [45] will allow us to identify the genome wide profiling of VEGFR2-
DNA interactome and therefore contribute to the identification of genes 
regulated by VEGFR2. A good approach for these experiments could be using 
ECs cultured in the presence of VEGF, since in these conditions we could 
identify the most relevant genes involved in the angiogenic response that are 
regulated by VEGFR2. In these conditions we could combine the VEGFR2 
DNA-binding activity profile obtained by ChIP-Seq with a full transcriptome 
analysis using RNA-Seq, thereby defining not only the gene targets regulated 
by VEGFR2 but also their biological outcome. However, this approach would 
also identify genes regulated by members of the VEGF pathway independently 
of nuclear VEGFR2, requiring further validation of the selected targets.  
Different aspects of this new molecular pathway remain to be defined. For 
instance, it is not clear if VEGFR2 binds directly to a consensus sequence in 
the VEGFR2 promoter or if Sp1 or other nuclear protein mediates the 
observed VEGFR2 DNA binding activity. We cannot exclude that VEGFR2 
binds directly to DNA and that the nuclear effects observed are directly 
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mediated by VEGFR2. The analysis of the binding profiles obtained in      
ChIP-Seq could help us to identify a consensus-binding pattern of VEGFR2. If 
the sequencing profiling of the VEGFR2 binding coincides with known binding 
sequences for other transcription factors, such as Sp1 or others, it could 
indicate that VEGFR2 is associated with these transcription factors and not 
directly bound to DNA. Conversely, a conserved VEGFR2 binding pattern 
throughout the genome without overlapping with other established 
transcription factor binding sequences could indicate that VEGFR2 binds 
directly to DNA and could be a good approach to identify its consensus 
binding sequence.  
Another useful approach to identify a potential DNA binding sequence for 
VEGFR2 is an in vitro PCR-based approach named cyclic amplification and 
selection of targets (CASTing), [46]. However, this technique requires the use 
of purified proteins, which could be experimentally challenging in the case of 
full-length VEGFR2, since this is an insoluble protein comprising a 
hydrophobic transmembrane domain, making its purification extremely difficult.  
CONCLUDING REMARKS  
The findings compiled in this thesis can have a great impact in the vascular 
biology field and contribute to a better understanding of the molecular 
mechanisms involved in angiogenesis and to reveal new mechanisms of 
resistance to anti-angiogenic therapies.  
The nuclear translocation of VEGFR2 and the regulation of its own expression 
impact the current model of vessel sprouting. This model predicts that ECs, 
exposed to the highest VEGF levels, gain a competitive advantage to acquire 
a tip-cell fate and position in the sprout [47]. It was also recently shown that 
this effect is mediated by elevated VEGFR2 levels that promote an 
upregulation of DLL4 levels [48]. The elevated VEGFR2 levels in cells 
exposed to higher levels of VEGF could be explained by our findings indicating 
that VEGFR2 is involved in the regulation of its own transcription by a possible 
VEGFR2 positive feedback loop. Therefore, we can speculate that in vivo, the 
higher levels of VEGFR2 observed at tip cells might be regulated by the 
GENERAL DISCUSSION 
 
 146 
nuclear activity of the receptor in these cells. Consistent with this idea, it was 
recently shown that the internalization of VEGFR2 is required for VEGF-
induced tip cell filopodial extension in vivo [26]. Elevated levels of DLL4 in tip 
cells activate Notch signaling in neighboring cells that produces a reduction of 
VEGF-mediated signaling, which results in the downregulation of DLL4 and 
VEGFR2 expression [47,48,49,50,51,52,53]. As a consequence these cells 
acquire stalk cell fate [48]. This is consistent with our wound healing assays in 
vitro where increased levels of nuclear VEGF-VEGFR2 were only observed in 
ECs close to wound edges early after injury, suggesting an increase in 
VEGFR2 levels after wounding and its normalization upon recovery.  
In the context of tumor angiogenesis, the nuclear internalization of VEGFR2 
and its involvement in the regulation of its own transcription might also have a 
great impact, since it has been reported that some tumor cells can have a 
constitutive nuclear localization of VEGFR2 [4,7,8], mediated by autocrine 
loops of VEGF and VEGFR2 [7]. Therefore, it would be important to analyse 
the effects of the anti-angiogenic agents, such as Bevacizumab and Sunitinib, 
in the nuclear internalization and transcriptional activity of VEGFR2 in tumor 
cells, as a constitutive VEGFR2 transcriptional activity could be implicated in 
the mechanisms of resistance to anti-VEGF therapies.  
Overall, the novel biological activity of VEGFR2 discovered during this work 
will contribute for a better understanding of the molecular mechanisms of 
angiogenesis and possibly help the improvement and future design of novel 
therapeutic approaches. 
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Appendix A – Table 1. VEGFR-2-interacting proteins as identified by MS analysis. Proteins listed according to their Mascot score.
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